WO2019035605A9 - 리포펩티드가 삽입된 리포좀을 유효성분으로 포함하는 백신 아쥬반트 및 이의 용도 - Google Patents
리포펩티드가 삽입된 리포좀을 유효성분으로 포함하는 백신 아쥬반트 및 이의 용도 Download PDFInfo
- Publication number
- WO2019035605A9 WO2019035605A9 PCT/KR2018/009173 KR2018009173W WO2019035605A9 WO 2019035605 A9 WO2019035605 A9 WO 2019035605A9 KR 2018009173 W KR2018009173 W KR 2018009173W WO 2019035605 A9 WO2019035605 A9 WO 2019035605A9
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antigen
- vaccine
- pam
- lipo
- poly
- Prior art date
Links
- 239000002502 liposome Substances 0.000 title claims abstract description 37
- 239000012646 vaccine adjuvant Substances 0.000 title claims description 11
- 229940124931 vaccine adjuvant Drugs 0.000 title claims description 11
- 239000004615 ingredient Substances 0.000 title description 4
- 239000000427 antigen Substances 0.000 claims abstract description 255
- 108091007433 antigens Proteins 0.000 claims abstract description 255
- 102000036639 antigens Human genes 0.000 claims abstract description 255
- 229960005486 vaccine Drugs 0.000 claims abstract description 178
- 239000000203 mixture Substances 0.000 claims abstract description 113
- 241000701085 Human alphaherpesvirus 3 Species 0.000 claims abstract description 91
- 108010028921 Lipopeptides Proteins 0.000 claims abstract description 50
- 239000002671 adjuvant Substances 0.000 claims abstract description 40
- 230000001932 seasonal effect Effects 0.000 claims abstract description 30
- 241000712461 unidentified influenza virus Species 0.000 claims abstract description 30
- 238000000034 method Methods 0.000 claims abstract description 17
- 241000710842 Japanese encephalitis virus Species 0.000 claims abstract description 9
- 229940115272 polyinosinic:polycytidylic acid Drugs 0.000 claims description 165
- 101000807236 Human cytomegalovirus (strain AD169) Membrane glycoprotein US3 Proteins 0.000 claims description 115
- 230000024932 T cell mediated immunity Effects 0.000 claims description 52
- 238000004519 manufacturing process Methods 0.000 claims description 32
- 241000700605 Viruses Species 0.000 claims description 17
- -1 lipid polysaccharide Chemical class 0.000 claims description 12
- 206010028980 Neoplasm Diseases 0.000 claims description 10
- 201000011510 cancer Diseases 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 10
- 239000013543 active substance Substances 0.000 claims description 9
- 239000000126 substance Substances 0.000 claims description 9
- 239000004480 active ingredient Substances 0.000 claims description 8
- 208000015181 infectious disease Diseases 0.000 claims description 7
- 229920001282 polysaccharide Polymers 0.000 claims description 6
- 239000005017 polysaccharide Substances 0.000 claims description 6
- 150000004676 glycans Chemical class 0.000 claims description 5
- 229940035032 monophosphoryl lipid a Drugs 0.000 claims description 5
- 230000002265 prevention Effects 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 102000003886 Glycoproteins Human genes 0.000 claims description 3
- 108090000288 Glycoproteins Proteins 0.000 claims description 3
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims description 3
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims description 3
- 230000029662 T-helper 1 type immune response Effects 0.000 claims description 3
- 244000052769 pathogen Species 0.000 claims description 3
- 230000001717 pathogenic effect Effects 0.000 claims description 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 3
- 108010040721 Flagellin Proteins 0.000 claims description 2
- 102000040430 polynucleotide Human genes 0.000 claims description 2
- 108091033319 polynucleotide Proteins 0.000 claims description 2
- 239000002157 polynucleotide Substances 0.000 claims description 2
- 230000028996 humoral immune response Effects 0.000 abstract description 39
- 208000007514 Herpes zoster Diseases 0.000 abstract description 25
- 230000021633 leukocyte mediated immunity Effects 0.000 abstract description 3
- 239000002131 composite material Substances 0.000 abstract 1
- HIHOWBSBBDRPDW-PTHRTHQKSA-N [(3s,8s,9s,10r,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl] n-[2-(dimethylamino)ethyl]carbamate Chemical compound C1C=C2C[C@@H](OC(=O)NCCN(C)C)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HIHOWBSBBDRPDW-PTHRTHQKSA-N 0.000 description 149
- 108090000978 Interleukin-4 Proteins 0.000 description 64
- 102000004388 Interleukin-4 Human genes 0.000 description 64
- 150000002632 lipids Chemical class 0.000 description 62
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 description 54
- 108010008038 Synthetic Vaccines Proteins 0.000 description 48
- 229940124551 recombinant vaccine Drugs 0.000 description 48
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 42
- 238000002965 ELISA Methods 0.000 description 41
- 102000004127 Cytokines Human genes 0.000 description 38
- 108090000695 Cytokines Proteins 0.000 description 38
- 238000009472 formulation Methods 0.000 description 35
- 238000002255 vaccination Methods 0.000 description 33
- 241000699670 Mus sp. Species 0.000 description 29
- 101900123149 Varicella-zoster virus Envelope glycoprotein E Proteins 0.000 description 29
- 210000004027 cell Anatomy 0.000 description 29
- 238000004458 analytical method Methods 0.000 description 27
- 102100037850 Interferon gamma Human genes 0.000 description 26
- 108010074328 Interferon-gamma Proteins 0.000 description 26
- 238000002156 mixing Methods 0.000 description 24
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 23
- 230000005847 immunogenicity Effects 0.000 description 20
- 230000028327 secretion Effects 0.000 description 18
- 238000002360 preparation method Methods 0.000 description 17
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 13
- 238000011510 Elispot assay Methods 0.000 description 13
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 13
- 230000002238 attenuated effect Effects 0.000 description 13
- 241000699666 Mus <mouse, genus> Species 0.000 description 11
- 102100040247 Tumor necrosis factor Human genes 0.000 description 10
- 206010057190 Respiratory tract infections Diseases 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol group Chemical group OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 230000028993 immune response Effects 0.000 description 9
- 210000001744 T-lymphocyte Anatomy 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 8
- 210000000952 spleen Anatomy 0.000 description 8
- 229940037003 alum Drugs 0.000 description 7
- 238000005215 recombination Methods 0.000 description 7
- 230000006798 recombination Effects 0.000 description 7
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- SNKAWJBJQDLSFF-NVKMUCNASA-N 1,2-dioleoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC SNKAWJBJQDLSFF-NVKMUCNASA-N 0.000 description 5
- 208000036142 Viral infection Diseases 0.000 description 5
- 230000003053 immunization Effects 0.000 description 5
- 238000002649 immunization Methods 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 239000013612 plasmid Substances 0.000 description 5
- 230000003248 secreting effect Effects 0.000 description 5
- 230000009385 viral infection Effects 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 4
- 241000283707 Capra Species 0.000 description 4
- 201000006082 Chickenpox Diseases 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 206010046980 Varicella Diseases 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 238000004587 chromatography analysis Methods 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 210000004989 spleen cell Anatomy 0.000 description 4
- 230000003393 splenic effect Effects 0.000 description 4
- 229940124597 therapeutic agent Drugs 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 238000008157 ELISA kit Methods 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 229960004150 aciclovir Drugs 0.000 description 3
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 210000000612 antigen-presenting cell Anatomy 0.000 description 3
- 230000000890 antigenic effect Effects 0.000 description 3
- 239000003443 antiviral agent Substances 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- 238000004040 coloring Methods 0.000 description 3
- 150000004665 fatty acids Chemical group 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 230000003308 immunostimulating effect Effects 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 230000003449 preventive effect Effects 0.000 description 3
- 230000007420 reactivation Effects 0.000 description 3
- 108091008146 restriction endonucleases Proteins 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 210000004988 splenocyte Anatomy 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 2
- KWVJHCQQUFDPLU-YEUCEMRASA-N 2,3-bis[[(z)-octadec-9-enoyl]oxy]propyl-trimethylazanium Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(C[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC KWVJHCQQUFDPLU-YEUCEMRASA-N 0.000 description 2
- XHTLLPJFZIYMHD-UHFFFAOYSA-N 4-(trifluoromethylsulfonyl)benzene-1,2-diamine Chemical compound NC1=CC=C(S(=O)(=O)C(F)(F)F)C=C1N XHTLLPJFZIYMHD-UHFFFAOYSA-N 0.000 description 2
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 239000012619 Butyl Sepharose® Substances 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 241000701022 Cytomegalovirus Species 0.000 description 2
- 229920002271 DEAE-Sepharose Polymers 0.000 description 2
- 206010014596 Encephalitis Japanese B Diseases 0.000 description 2
- 101000867232 Escherichia coli Heat-stable enterotoxin II Proteins 0.000 description 2
- 208000003098 Ganglion Cysts Diseases 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 241000701806 Human papillomavirus Species 0.000 description 2
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 2
- 201000005807 Japanese encephalitis Diseases 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 101001002703 Mus musculus Interleukin-4 Proteins 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- 241000607768 Shigella Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- 208000005400 Synovial Cyst Diseases 0.000 description 2
- 241000711975 Vesicular stomatitis virus Species 0.000 description 2
- 230000003602 anti-herpes Effects 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 210000004443 dendritic cell Anatomy 0.000 description 2
- 238000011033 desalting Methods 0.000 description 2
- OGQYPPBGSLZBEG-UHFFFAOYSA-N dimethyl(dioctadecyl)azanium Chemical compound CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCCCCCC OGQYPPBGSLZBEG-UHFFFAOYSA-N 0.000 description 2
- ORMNPSYMZOGSSV-UHFFFAOYSA-N dinitrooxymercury Chemical compound [Hg+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O ORMNPSYMZOGSSV-UHFFFAOYSA-N 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 231100000655 enterotoxin Toxicity 0.000 description 2
- 235000019441 ethanol Nutrition 0.000 description 2
- 239000010408 film Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 229920006008 lipopolysaccharide Polymers 0.000 description 2
- 208000004296 neuralgia Diseases 0.000 description 2
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 229940021648 varicella vaccine Drugs 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- MWRBNPKJOOWZPW-NYVOMTAGSA-N 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine zwitterion Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP(O)(=O)OCCN)OC(=O)CCCCCCC\C=C/CCCCCCCC MWRBNPKJOOWZPW-NYVOMTAGSA-N 0.000 description 1
- QTWJRLJHJPIABL-UHFFFAOYSA-N 2-methylphenol;3-methylphenol;4-methylphenol Chemical compound CC1=CC=C(O)C=C1.CC1=CC=CC(O)=C1.CC1=CC=CC=C1O QTWJRLJHJPIABL-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- COCMHKNAGZHBDZ-UHFFFAOYSA-N 4-carboxy-3-[3-(dimethylamino)-6-dimethylazaniumylidenexanthen-9-yl]benzoate Chemical compound C=12C=CC(=[N+](C)C)C=C2OC2=CC(N(C)C)=CC=C2C=1C1=CC(C([O-])=O)=CC=C1C(O)=O COCMHKNAGZHBDZ-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 1
- 239000004254 Ammonium phosphate Substances 0.000 description 1
- 240000003291 Armoracia rusticana Species 0.000 description 1
- 235000011330 Armoracia rusticana Nutrition 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000588832 Bordetella pertussis Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 239000004255 Butylated hydroxyanisole Substances 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 206010008631 Cholera Diseases 0.000 description 1
- 108010049048 Cholera Toxin Proteins 0.000 description 1
- 102000009016 Cholera Toxin Human genes 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 241000193449 Clostridium tetani Species 0.000 description 1
- 101150074155 DHFR gene Proteins 0.000 description 1
- 108010041986 DNA Vaccines Proteins 0.000 description 1
- 229940021995 DNA vaccine Drugs 0.000 description 1
- 101150114656 DPOL gene Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 241000590002 Helicobacter pylori Species 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- 101000626607 Herpetosiphon aurantiacus Putative type II restriction enzyme HgiDII Proteins 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 229940124726 Japanese encephalitis vaccine Drugs 0.000 description 1
- 241001092142 Molina Species 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 102000005348 Neuraminidase Human genes 0.000 description 1
- 108010006232 Neuraminidase Proteins 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108010081690 Pertussis Toxin Proteins 0.000 description 1
- 241001454523 Quillaja saponaria Species 0.000 description 1
- 235000009001 Quillaja saponaria Nutrition 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 210000000447 Th1 cell Anatomy 0.000 description 1
- 101710123661 Venom allergen 5 Proteins 0.000 description 1
- 229940124925 Zostavax Drugs 0.000 description 1
- 239000001099 ammonium carbonate Substances 0.000 description 1
- 235000012501 ammonium carbonate Nutrition 0.000 description 1
- 229910000148 ammonium phosphate Inorganic materials 0.000 description 1
- 235000019289 ammonium phosphates Nutrition 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 229940001442 combination vaccine Drugs 0.000 description 1
- 229930003836 cresol Natural products 0.000 description 1
- 229940013361 cresol Drugs 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- MNNHAPBLZZVQHP-UHFFFAOYSA-N diammonium hydrogen phosphate Chemical compound [NH4+].[NH4+].OP([O-])([O-])=O MNNHAPBLZZVQHP-UHFFFAOYSA-N 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- MWRBNPKJOOWZPW-CLFAGFIQSA-N dioleoyl phosphatidylethanolamine Chemical class CCCCCCCC\C=C/CCCCCCCC(=O)OCC(COP(O)(=O)OCCN)OC(=O)CCCCCCC\C=C/CCCCCCCC MWRBNPKJOOWZPW-CLFAGFIQSA-N 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- 229960003983 diphtheria toxoid Drugs 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 101150072564 gE gene Proteins 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229940037467 helicobacter pylori Drugs 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 229940124725 herpes simplex vaccine Drugs 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 229940031551 inactivated vaccine Drugs 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 229960003971 influenza vaccine Drugs 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 210000000578 peripheral nerve Anatomy 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 108010021711 pertactin Proteins 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 239000006152 selective media Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 230000036332 sexual response Effects 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229940079827 sodium hydrogen sulfite Drugs 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 229940048086 sodium pyrophosphate Drugs 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000004114 suspension culture Methods 0.000 description 1
- 229960000814 tetanus toxoid Drugs 0.000 description 1
- 235000019818 tetrasodium diphosphate Nutrition 0.000 description 1
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000009210 therapy by ultrasound Methods 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
- A61K39/25—Varicella-zoster virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- the present invention relates to a vaccine adjuvant comprising a lipopeptide having a lipopeptide inserted therein as an active ingredient and a use thereof.
- Herpes Zoster is caused by Varicella-Zoster Virus (VZV) and is a skin disorder that occurs in the spinal cord or sensory nerves of the brain.
- VZV Varicella-Zoster Virus
- the virus penetrates into peripheral nerve cells after proliferation in epidermal and dermal regions of the skin, and is present in latent state.
- varicella develops and oscillates, and if it is latent in the ganglion and then becomes less resistant to the body, the VZV reactivates and appears as a herpes zoster.
- VZV reactivation and onset of herpes zoster are associated with weakening of T cell-mediated cellular immune responses, especially in elderly people and those receiving immunosuppressive treatment.
- a bulbous lesion appears and even if the lesion is restored, the aftereffects of the neuralgia remain.
- Neuralgia, once it occurs, is difficult to cure and it causes poor quality of life due to severe pain.
- VZV When VZV is transmitted, neglecting the initial response and neglecting the incubation period, eventually, reactivation of VZV causes herpes zoster and accompanies severe pain. In this case, generally, an antiviral agent is administered, but it has a problem that it is difficult to induce the death or inhibition of the activity of VZV, which is likely to have resistance in the body during the incubation period.
- antiviral agents for VZV include ascrovirus, foot acyclovir, and palmyclover. Among them, ascrovirus is the most commercially available. However, acyclovir can be significantly effective only when administered within 24 hours after varicella. In other words, the acyclovir is not effective enough as an antiviral agent when it is prescribed 24 hours after viral infection or chickenpox rash, or after the occurrence of herpes zoster due to reactivation of VZV.
- herpes zoster As the number of elderly people and immunosuppressed patients increases, the incidence of herpes zoster is rapidly increasing in Korea, but there is no essential treatment method, so it is necessary to develop a vaccine that can prevent it.
- the efficacy of the anti-herpes zoster vaccine currently on the market has been recognized in clinical trials, the efficacy of vaccination against herpes zoster is only 50% lower than that of vaccine.
- currently available anti-herpes zoster vaccine is an attenuated live vaccine, so there is a limitation in administration to immunosuppressed patients with a high incidence of herpes zoster, pregnant women, and possibly pregnant people.
- the herpes zoster is latent in the ganglion and the body resistance is low, the VZV is reactivated. Therefore, it is more important to induce the cellular immune response than the humoral immune response in order to treat it. Therefore, it is necessary to develop a herpes zoster vaccine that can induce an effective and safe cellular immune response.
- the molecular pattern of the antigen affects the outcome of the immune response. This is particularly important when the whole pathogenic microorganism is used as an antigen.
- These antigens are mixed with several kinds of pathogen associated molecular pattern (PAMP) ligands such as lipopolysaccharide, nucleic acid, lipid protein or protein.
- PAMP pathogen associated molecular pattern
- the pathogen recognition receptor (PRR) on the surface of the antigen presenting cell is involved in the type of immune response induced by stimulating signals to induce various co-stimulatory molecules and cytokines by recognizing PAMP.
- interferon gamma and IL-12 induce Th1 cell responses that are important for immune responses to viral infections.
- the Th1 type of immune response induces more IgG2a or IgG2b production and a strong cellular immune response.
- Korean Patent Registration No. 10-1723605 discloses a DNA vaccine composition for preventing and treating herpes zoster which contains a plasmid containing an insertion site of a VZV-derived gene encoding a protein of VZV
- 10-2014-0022799 discloses a varicella vaccine and a varicella vaccine comprising as an active ingredient a genomic DNA of VZV MVA06 isolated from a Korean patient and a protein encoded by the open reading frame thereof.
- the present inventors have conducted studies to develop a herpes simplex vaccine which induces not only a humoral immune response but also a cellular immune response with high safety.
- the inventors of the present invention have found that a liposome-type conjugate conjugate containing Pam3-CSKKKK (Pam3CSK4) lipopeptide and lipid
- the vaccine composition comprising poly (I: C) and an antigen in the prepared adjuvant, as well as a humoral immune response against a recombinant protein antigen having a small molecular weight, Respectively.
- the vaccine composition of the present invention may be prepared by using various lipopeptides including Pam3-CSKKK, Dhc-SKKKK, PamDhc-SKKKK, etc., as well as the gE (glycoprotein E) antigen of Varicella- (Glycoprotein E) or seasonal inactivated influenza virus (AGE) antigens.
- gE glycoprotein E
- AGE seasonal inactivated influenza virus
- An object of the present invention is to provide a vaccine adjuvant comprising a lipopeptide having a lipopeptide inserted therein as an active ingredient, a vaccine composition comprising the vaccine and a use thereof.
- the present invention provides a vaccine adjuvant comprising liposome having lipopeptide inserted therein as an active ingredient.
- the present invention also provides a vaccine composition comprising an adjuvant and an antigen of the present invention.
- the present invention also provides a vaccine composition for preventing or treating viral infection comprising the vaccine composition of the present invention as an effective ingredient.
- the present invention also provides a preventive or therapeutic agent for cancer comprising the vaccine composition of the present invention as an effective ingredient.
- the present invention also provides a method of preventing or treating infection of a virus comprising administering the vaccine composition of the present invention to a subject.
- the present invention also provides a method of preventing or treating cancer, comprising administering the vaccine composition of the present invention to a subject.
- the present invention also provides the use of the vaccine composition of the present invention for use in the manufacture of a medicament for the prevention or treatment of infection of a virus.
- the present invention provides the use of the vaccine composition of the present invention for use in the manufacture of a medicament for the prevention or treatment of cancer.
- the vaccine composition comprising Lipo-Pam, which is a complex adjuvant comprising the lipids and lipopeptides of the present invention, can induce a humoral immune response as well as a high level of cellular immune response, and can be used not only as a gE antigen of Varicella- But also when gE antigen of seasonal influenza virus or seasonal inactivated influenza virus antigen is used, the composition of the present invention can be used commercially.
- FIG. 1 is a schematic diagram showing the production of a pPGXII-VZV gE plasmid in which a gE gene of VZV is introduced into a pPGXII vector.
- FIG. 2A is an SDS-PAGE analysis of purification steps of VZV recombinant gE antigen.
- M is a marker for confirming the size
- 1 is a cell culture broth
- 2 is a butyl-Sepharose chromatography eluate
- 3 is DEAE-Sepharose chromatography eluent
- 4 is CHT chromatography eluate
- 5 is SP- Sepharose chromatography
- the eluent and 6 means after concentration-desalting filtration.
- Figure 2b shows the Western blot results of the recombinant gE antigen of the final purified VZV. 6 means after concentration-desalting filtration.
- FIG. 3A is a graph comparing the total IgG antibody to the recombinant gE antigen of VZV of the recombinant vaccine according to the production method of the liposome and the ratio of components contained in the liposome.
- FIG. 3B is a graph comparing the isotype of the antibody against the recombinant gE antigen of VZV of the recombinant vaccine according to the production method of the liposome and the proportion of components contained in the liposome.
- 4A is a graph comparing ELISPOT analysis results of IFN-y and IL-4 with recombinant gE antigens of VZV of a recombinant vaccine according to the production method of liposome and components contained in the liposome.
- 4B is a graph comparing ELISA analysis results of IFN-y, IL-4 and TNF-a with recombinant gE antigen of VZV of recombinant vaccine according to the production method of liposome and components contained in the liposome.
- FIG. 5 is a view showing the structure of a vaccine prepared using Lipo-pam using a confocal microscope.
- Figure 6 shows the total IgG antibody titers for vaccine compositions comprising adjuvant and recombinant gE antigen of VZV prepared by varying lipid and Pam3-CSKKKK composition and poly (I: C) capacity in Lipo-pam
- FIG. 6 shows the total IgG antibody titers for vaccine compositions comprising adjuvant and recombinant gE antigen of VZV prepared by varying lipid and Pam3-CSKKKK composition and poly (I: C) capacity in Lipo-pam
- 7A is a graph showing the effect of IFN-? And IL on the vaccine composition comprising the recombinant gE antigen of adjuvant and VZV prepared by varying the lipid contained in Lipo-pam and the composition of Pam3-CSKKKK and poly (I: C) -4 in the ELISPOT assay.
- FIG. 7B is a graph showing the effect of IFN- ⁇ , IL (1: C) on the vaccine composition comprising adjuvant and recombinant gE antigen of VZV prepared by varying the lipid contained in Lipo-pam and the composition of Pam3-CSKKKK and poly -4 and TNF- ?.
- FIG. 8 is a graph comparing total IgG antibody titers against vaccine compositions comprising adjuvants prepared by varying the lipid capacities of Lipo-pam and recombinant gE antigens of different doses of VZV.
- Figure 9a compares ELISPOT analysis of IFN-y and IL-4 to vaccine compositions comprising adjuvants prepared with different lipid capacities in Lipo-pam and recombinant gE antigens of different doses of VZV Graph.
- FIG. 9b shows ELISA analysis of IFN-y, IL-4 and TNF-alpha for vaccine compositions containing adjuvant and different doses of lipid contained in lipo-pam and recombinant gE antigens of different doses of VZV Fig.
- Figure 10 compares total IgG antibody titers to vaccine compositions comprising adjuvants prepared by varying the lipid and poly (I: C) content of Lipo-pam and recombinant gE antigens of different doses of VZV Graph.
- Figure 11a shows the effect of IFN-y and IL-4 on the vaccine composition comprising adjuvant and different doses of VZV recombinant gE antigen prepared by varying the lipid and poly (I: C) capacities of Lipo-pam Of the ELISPOT assay.
- FIG. 11B shows the effect of IFN-.gamma., IL-4 on the adjuvant prepared by varying the lipid and poly (I: C) capacity of Lipo-pam and the vaccine composition containing recombinant gE antigen of different dose of VZV And TNF-a.
- Figure 12 is a graph comparing total IgG antibody titers against recombinant gE antigens of VZV of recombinant vaccine according to attenuated herpes zoster vaccine and adjuvant formulation.
- 13A is a graph comparing ELISPOT analysis results of IFN-y and IL-4 to recombinant gE antigens of VZV of recombinant vaccine according to attenuated herpes zoster vaccine and adjuvant formulation.
- FIG. 13B is a graph comparing ELISA results of IFN-y, IL-4 and TNF-a with recombinant gE antigens of VZV of recombinant vaccine according to attenuated herpes zoster vaccine and adjuvant formulation.
- FIG. 14 is a graph comparing the frequency of CD4 + T cells secreting a cytokine of a recombinant vaccine according to an attenuated herpes zoonotic vaccine and an adjuvant formulation.
- 15 is a graph comparing the multifunctional activity of CD4 + T cells of the recombinant vaccine according to the attenuated herpes zoonotic vaccine and the adjuvant formulation.
- 16 is a graph comparing total IgG antibody titers against recombinant VZV gE antigens of the recombinant vaccine according to the attenuated target herzin vaccine and the adjuvant composition and formulation.
- 17A is a graph comparing ELISPOT analysis results of IFN-y and IL-4 against recombinant VZV gE antigens of recombinant vaccines according to the attenuated herpes zoster vaccine and adjuvant composition and formulation.
- Figure 17B is a graph comparing ELISA results of IFN-y, IL-4 and TNF- alpha against recombinant VZV gE antigens of recombinant vaccines according to the attenuated herpes zoster vaccine and adjuvant composition and formulation.
- 19A is a graph comparing ELISPOT analysis results of IFN-y and IL-4 with recombinant gE antigens of VZV of recombinant vaccine according to the composition and production method of Lipo-pam.
- FIG. 19B is a graph comparing ELISA results of IFN-y, IL-4 and TNF-a with recombinant gE antigen of VZV of recombinant vaccine according to the composition and production method of Lipo-pam.
- FIG. 20 shows the results of a recombinant vaccine according to the type and amount of lipid, the kind of immunologically active substance, and the recombinant gE antigenic capacity of VZV 0.0 > IgG < / RTI > antibody against recombinant gE antigen of VZV.
- 21A is a graph comparing ELISPOT analysis results of IFN-y and IL-4 with recombinant gE antigens of VZV of recombinant vaccine according to lipid type and dose, type of immunologically active substance, and recombinant gE antigen dose of VZV.
- Figure 21B compares the ELISA results of IFN-y, IL-4 and TNF-a with recombinant gE antigens of VZV of recombinant vaccine according to lipid type and dosage, type of immunologically active substance and recombinant gE antigen dose of VZV It is a graph.
- FIG. 22 is a graph comparing total IgG antibody titers against recombinant VZV recombinant gE antigens of recombinant vaccines according to the types of lipopeptides constituting Lipo-pam.
- 23A is a graph comparing ELISPOT analysis results of IFN- ⁇ and IL-4 with respect to VZV recombinant gE antigen of a recombinant vaccine according to the kind of lipopeptides constituting Lipo-pam.
- 23B is a graph comparing the results of ELISA analysis of IFN-y, IL-4 and TNF-alpha against VZV recombinant gE antigen of recombinant vaccine according to the kind of lipopeptide constituting Lipo-pam.
- 24A is a graph comparing total IgG antibody titers against recombinant JEV gE antigens.
- Figure 24B is a graph comparing total IgG antibody titers against inactivated JEV antigens to recombinant JEV gE antigens.
- 25A is a graph comparing ELISPOT analysis results of IFN-y and IL-4 against the gE antigen of Japanese encephalitis virus of recombinant vaccine according to the adjuvant formulation.
- 25B is a graph comparing the results of ELISA analysis of IFN-y, IL-4 and TNF-alpha against gE antigen of Japanese encephalitis virus of recombinant vaccine according to the adjuvant formulation.
- FIG. 26 is a graph comparing total IgG antibody titers against four strains (H1N1, H3N2, B-Y, or B-V) of seasonal inactivated influenza virus according to the adjuvant formulation.
- Figure 27 shows ELISPOT analysis of IFN-y against four strains of seasonal inactivated influenza virus according to the adjuvant formulation (H1N1, H3N2, B-Y or B-V).
- Figure 28 shows ELISPOT analysis of IL-4 against four strains of seasonal inactivated influenza virus (H1N1, H3N2, B-Y or B-V) according to the adjuvant formulation.
- Figure 30 shows the results of ELISA analysis of TNF-a against four strains of seasonal inactivated influenza virus (H1N1, H3N2, B-Y or B-V).
- Figure 31 shows the results of ELISA analysis of IL-4 against four strains of seasonal inactivated influenza virus (H1N1, H3N2, B-Y, or B-V).
- the present invention provides a vaccine adjuvant comprising as an active ingredient a lipopeptide having a lipopeptide inserted therein.
- the lipopeptide may be composed of a fatty acid bonded to a glycerol molecule and various amino acids.
- the number of amino acids constituting the fatty acid or lipopeptide in the glycerol molecule may be one or more.
- the fatty acid and the amino acid may be chemically modified.
- the lipopeptide may be part of a molecule derived from gram-positive or gram-negative bacteria or mycoplasma, or may be a lipid protein in its entire molecular form.
- the lipopeptide may be selected from the group consisting of Pam3Cys-SKKKK, Pam3-CSKKKK, PHC-SKKKK, Ole2PamCys-SKKKK, Pam2Cys- SKKKK, PamCys (Pam) -SKKKK, Ole2Cys- SKKKK, Myr2Cys-SKKKK, PamDhc- Dhc-SKKKK, and FSL-1.
- the lipopeptides may be added to liposomes at concentrations ranging from 20 to 250, 20 to 50, 50 to 250, 150 to 250, 50 to 150, 20 to 2500, 20 to 500, 50 to 2500, 150 to 2500, Can be inserted.
- the liposome may be composed of lipid.
- the lipid may be a cation, an anion or a neutral lipid.
- the lipid may be selected from the group consisting of DOTAP (1,2-Dioleoyl-3-Trimethylammonium-Propane), DOPE (1,2-dioleoyl-sn-glycero-3-phosphoethanolamine), DDA (Dimethyldioctadecylammonium), DC- (1,2-Dioleoyl-sn-Glycero-3- [Phospho-rac- (1-glycerol)]), DPPC (1,2- dipalmitoyl-sn-glycero-3-phosphocholine, DOPC (1,2-dioleoyl-sn-glycero-3-phosphocholine) and cholesterol.
- DOTAP 1,2-Dioleoyl-3-Trimethylammonium-Propane
- DOPE 1,2-dioleoyl-sn-
- the vaccine adjuvant according to the present invention may further comprise an immunologically active substance.
- the immunoactive substance may be any one selected from the group consisting of poly (I: C), QS21, monophosphoryl lipid A (MPLA), CpG and flagellin.
- the poly (I: C) has been used as a powerful derivative of type 1 interferon in in vitro and in vivo studies. Furthermore, poly (I: C) has been shown to stably and maturely form dendritic cells, the most potent antigen presenting cells in mammals (Rous, R. et al. 2004, International Immunol, 16: 767-773).
- IL-12 is a potent IL-12 inducer that stimulates the immune response to develop Th1, leading to cell-mediated immune responses and IgG2a or IgG2b antibody formation to be.
- the poly (I: C) may be 50 to 5,000 bp in length. Wherein the poly (I: C) has a weight average molecular weight of from 10 to 150, from 10 to 90, from 10 to 50, from 10 to 30, from 30 to 60, from 30 to 90, from 30 to 150, from 30 to 50, from 10 to 1500, 500, 10 to 300, 30 to 600, 30 to 900, 30 to 1500 or 30 to 500 ⁇ ⁇ / dose.
- the QS21 is a fraction of a saponin substance called triterpene glucoside having a molecular weight of 1990.14 Da extracted from the bark of Quillaja saponaria Molina of South America.
- QS21 When used in conjunction with lipids such as MPLA or cholesterol, QS21 is known to induce humoral and cellular immune responses by secretion of Th1 type cytokines in antigen presenting cells such as macrophages and dendritic cells.
- said QS21 is selected from the group consisting of 1 to 150, 1 to 90, 1 to 50, 1 to 30, 3 to 60, 3 to 90, 3 to 150, 3 to 50, 1 to 1500, 1 to 900, 1 to 500, , 3 to 600, 3 to 900, 3 to 1500, or 3 to 500 [mu] g / dose.
- the present invention also provides a vaccine composition comprising an adjuvant and an antigen of the present invention.
- the adjuvant may have the above-described characteristics.
- the adjuvant may include a lipopeptide having a lipopeptide inserted therein, and may further include an immunologically active substance.
- the antigen may be any substance capable of being recognized by the immune system of the host and capable of causing an immune response when it enters the host's body and may be a protein, a recombinant protein, a glycoprotein, a peptide, a polysaccharide, a lipopolysaccharide or a polynucleotide Lt; / RTI >
- the antigen may be a gE (glycoprotein E) antigen of Varicella-Zoster Virus; GE (glycoprotein E) antigen of Japanese encephalitis; A seasonal inactivated influenza virus antigen; The haemagglutinin and neuraminidase antigens of the influenza virus; Pertussis toxin antigen, filamentous haemagglutinin antigen and pertactin antigens of Bordetella pertussis; Antigens of human papilloma virus (HPV), climatic polysaccharide antigens of the
- the vaccine composition may additionally comprise buffers, isotonic agents, preservatives, stabilizers and solubilizing aids.
- buffers phosphate, acetate, ammonium phosphate, ammonium carbonate, citrate and the like can be used.
- the vaccine may induce a high cellular immune response as well as an antigenic-specific humoral immune response.
- the vaccine may enhance the Th1 immune response.
- Antibodies of IgG2a or IgG2b that promote Th1 immune responses effective against antiviral and anticancer immune responses are produced by cytokines produced by helper T cell 1 (Th1). Therefore, the vaccine composition of the present invention can also be used as a preventive or therapeutic agent for viral infection or cancer.
- recombinant Varicella-Chooster virus gE antigen see FIGS. 1 and 2
- mixed DC-Chol, DOPE or DPPC lipid with Pam3-CSKKKK, -Pam was prepared by adding poly (I: C) or QS21 as an immunologically active substance thereto, and the recombinant gE antigen of the prepared Barissera-Zoster virus was added thereto to prepare a recombinant vaccine against Barisella- .
- the recombinant vaccine showed that Pam3-CSKKKK forms a liposome together with lipid, and recombinant gE antigen of VZV forms a structure bound to the surface of liposome (FIG. 5).
- the recombinant vaccine induced not only the humoral immune response but also the cellular immune response (see FIGS. 3, 4 and 6 to 21).
- a recombinant vaccine prepared by mixing Lipo-pam with various types of lipopeptides together with DC-Chol and DPPC and adding the recombinant gE antigen of poly (I: C) and VZV to the Lipo-pam, Induced high cellular immune responses as well as sexual and immune responses (see Figures 22 and 23).
- a recombinant vaccine against Japanese encephalitis virus was prepared by adding poly (I: C) and recombinant gE antigen of Japanese encephalitis virus to Lipo-Pam prepared by mixing DC-Chol, DPPC and Pam3-CSKKKK, The vaccine highly induced the humoral immune response as well as the cellular immune response (see FIGS. 24 and 25).
- the vaccine composition comprising LIPO-Pam with the lipopeptide of the present invention as an adjuvant can be used commercially advantageously because it has an immune enhancing effect without limitation on the kind of antigen.
- the present invention provides a viral infection or cancer preventive or therapeutic agent comprising the vaccine composition of the present invention as an effective ingredient.
- the vaccine composition may have the characteristics as described above.
- the vaccine composition may comprise an adjuvant and an antigen.
- the adjuvant may include a liposome having a lipopeptide inserted therein, and may further comprise an immunostimulatory substance.
- the prophylactic or therapeutic agent of the present invention may include a pharmaceutically acceptable carrier, and may be formulated for human or veterinary administration and administered by various routes.
- the administration route can be administered by oral, intraperitoneal, intravenous, intramuscular, subcutaneous, intradermal, and other routes. Preferably, it is formulated and administered as an injection.
- the injectable solution may be an aqueous solvent such as physiological saline solution or ring gel solution, a non-aqueous solvent such as vegetable oil, higher fatty acid ester (e.g., oleic acid), alcohol (e.g., ethanol, benzyl alcohol, propylene glycol, glycerin, etc.) (Such as ascorbic acid, sodium hydrogen sulfite, sodium pyrophosphate, BHA, tocopherol, EDTA, etc.), emulsifiers, buffers for pH control, inhibition of microbial growth (For example, mercuric nitrate, thimerosal, benzalkonium chloride, phenol, cresol, benzyl alcohol, etc.), for example.
- aqueous solvent such as physiological saline solution or ring gel solution
- a non-aqueous solvent such as vegetable oil, higher fatty acid ester (e.g., oleic acid), alcohol (e.g., ethanol,
- the present invention also provides a method for preventing or treating infection of a virus or cancer, comprising administering a vaccine composition of the present invention to a subject.
- the vaccine composition may have the characteristics as described above.
- the vaccine composition may comprise an adjuvant and an antigen.
- the adjuvant may include a liposome having a lipopeptide inserted therein, and may further comprise an immunostimulatory substance.
- the subject may be a mammal, particularly a human.
- the administration can be a pharmaceutically effective amount.
- pharmaceutically effective amount means an amount that is capable of exhibiting a therapeutic effect and at the same time not causing side effects or serious or excessive immune response, and the exact dosage level may vary depending on the antigen to be included in the vaccine.
- the administration can be easily determined by those skilled in the art according to factors well known in the medical field such as the patient's age, body weight, health, sex and sensitivity to the drug, route of administration and administration method. The administration may be from one time to several times.
- the present invention provides the use of the vaccine composition of the present invention for use in the manufacture of a medicament for infecting a virus or preventing or treating cancer.
- the vaccine composition may have the characteristics as described above.
- the vaccine composition may comprise an adjuvant and an antigen.
- the adjuvant may include a liposome having a lipopeptide inserted therein, and may further comprise an immunostimulatory substance.
- a gene (SEQ ID NO: 1) was inserted so that a restriction enzyme recognition sequence (Nhe I at the 5 'region, Xho I at the 3' region) and a kozak sequence were contained in the outside region of the gE (glycoprotein E) gene expression site of VZV.
- a codon-optimized sequence was used for the CHO cell in which the anchor domain of the C-terminal was removed from ORF68 (glycoprotein E) of the entire genome of human herpesvirus type 3 (HHV-3) Respectively.
- VZV gE gene described in SEQ ID NO: 1 was digested with Nhe I and Xho I restriction enzymes and subcloned into the pPGXII vector to prepare a VZV gE expression plasmid pPGXII-VZV gE (FIG. 1).
- the pPGXII-VZV gE plasmid DNA prepared in Example ⁇ 1-1> was linearized with Ahd I restriction enzyme and then ligated with pDCH1P (dhfr) plasmid DNA using an electroporation method in a medium containing HT (Hypoxantine-Thymidine) In CHO DG44 (S) -EX cells cultured in passage 6. Subsequently, the transformed cells were inoculated into a medium containing HT, cultured in a selective medium containing no HT when the cells were fully grown, and initially adapted cells were obtained after about two weeks.
- Dot blotting and western blotting were carried out using the obtained cell groups, and four types of cells having excellent productivity among the initially adapted cell groups were selected.
- the selected strains were diluted by the limiting dilution method, and single cell lines were separated by inoculating 10 plates each into 96 well plates so as to be 1 cell / well.
- the isolated single cell line colonies were transferred to a 24 well plate and cultured. When the cell count was sufficient, the cells were transferred to Erlenmeyer flask and suspension culture was started. The cell viability was maintained at 95% or higher after 6th generation, and the productivity and stability were confirmed by culturing the cells at a constant rate.
- the final cell line was selected considering cell growth and productivity.
- EfficientFeed C + (Invitrogen) was added to 7.5 L of a jar fermenter containing the HyCell CHO (GE Healthcare) medium and the cell line finally selected in Example ⁇ 1-2> was added to 6.5 x 10 6 cells / mL .
- the permenter was operated at 32 ° C, DO 30%, and 100 rpm, and the pH of the medium was maintained at 6.8 or more.
- the content of glucose and lactic acid in the permerer was analyzed daily and the glucose content fell below 20 mmol / L, 45% D-glucose was added at a concentration of 1 v / v% for 10 days.
- the culture solution was recovered from the cells cultured in Example ⁇ 1-3 > using a depth-filter, and the recombinant gE antigen of VZV was purified therefrom.
- a four-step column chromatography using butyl-sepharose, DEAE-sepharose, CHT hydroxyapatite and SP-sepharose sequentially,
- the recombinant gE antigen of VZV was purified using the UF / DF method and the one - time UF / DF method for buffer exchange.
- the purified recombinant gE antigen of VZV showed a molecular weight of about 70 kDa (Fig. 2).
- DC-Chol and DOPE were dissolved in chloroform to prepare DC-Chol: DOPE liposome, respectively, and DC-Chol and DOPE were mixed at a ratio of 3: 7. And the organic solvent was vaporized with nitrogen gas. At this time, a thin film was formed on the base wall. The organic solvent remaining in the formed film was removed by being stored in a vacuum decicator for 1 hour. Distilled water was added to the completely dried lipid film and rehydrated for 10 minutes using a sonic bath. When a multilamellar vesicle (MLV) suspension was generated, a 2X buffer solution (pH 7.0) containing 300 mM NaCl in 20 mM sodium phosphate was added in the same amount as the distilled water.
- MLV multilamellar vesicle
- the resulting MLV was sonicated for 5 minutes for 3 minutes / 3 seconds (pulse on / off) for 5 minutes to produce a DC-Chol: DOPE liposome in the form of a small unilamellar vesicle (SUV) Respectively.
- Lipo-Pam was prepared by dissolving DC-Chol, DOPE and Pam3-CSKKKK in an organic solvent, then mixing DC-Chol and DOPE at a ratio of 3: 7 and adding Pam3-CSKKKK at 25 / / dose Chol: DOPE < / RTI > liposomes, except that the concentration was 100 ⁇ ⁇ / dose.
- control group L-pampo was prepared by mixing 25 ⁇ g of Pam3-CSKKKK, which is a lipopeptide, with 20 ⁇ g or 200 ⁇ g of poly (I: C).
- a test vaccine was prepared by adding 5 ⁇ g / dose of VZV gE antigen to the mixture.
- the mixture was sonicated and antigen was added to produce a test vaccine.
- the prepared vaccine was intramuscularly injected into female C57BL / 6 mice at 6 weeks of age (Orient Bio, Korea) at 2-week intervals.
- the total IgG antibody to the recombinant VZV gE antigen was determined by the following method. Specifically, purified VZV recombinant gE antigen was coated on a 96-well microplate at a concentration of 100 ng / well, and 1% bovine serum albumin was added to prevent non-specific binding. .
- Mouse IgG-HRP human IgG-HRP (horse radish heroxidase, KPL, USA) was added as a secondary antibody to the wells and incubated for 1 hour at 37 ° C. The reaction was carried out under the same conditions.
- the reacted microplate was washed and reacted with a coloring reagent TMB (3,3 ', 5,5'-tetramethyl benzidine) peroxidase substrate (KPL, USA) for 10 minutes at room temperature, , The OD was measured at 450 nm using an ELISA reader.
- Antibody was defined as the reciprocal of the antibody dilution factor representing the OD value corresponding to twice the negative control OD value.
- the isotype of the antibody against the recombinant gE antigen of VZV was determined by using goat anti-mouse IgG1, goat anti-mouse IgG2a, goat anti-mouse IgG2b or goat anti-mouse IgG2c as primary antibodies, All antibodies to recombinant gE antigens of VZV were analyzed in the same manner as the assay except that rabbit anti-goat IgG-HRP was used as an antibody.
- isotype analysis of antibodies against recombinant gE antigens of VZV showed IgG2b and IgG2c antibody titers to be higher than IgG1 in all test groups.
- the IgG2-type antibody was higher in the G3 group mixed with -pampo and the G6 group mixed with poly (I: C) in Lipo-pam (FIG. 3b).
- the cell-mediated immune response induced by the test vaccine administered in Example ⁇ 2-1> was obtained by isolating splenocytes from the spleen from the mice at 4 weeks after the 2nd vaccination, Assay and cytokine ELISA method.
- ELISPOT plates with antibodies against IFN-y or IL-4 were first washed with PBS, and complete media was added to activate the plates. After dispense of mouse spleen cells in the ELISPOT plate with 5 ⁇ 10 5 cells / well, ⁇ Example 1> The recombinant VZV gE antigen prepared into, 37 °C, in an incubator of 5% CO 2 conditions, 24 hours or in And reacted for 48 hours. The spleen cells were then removed and the plates were washed with PBS and the biotin conjugated antibody in the Mouse IFN-?
- ELISpot PLUS kit (Mabtech, Sweden) and Mouse IL-4 ELISpot PLUS kit (Mabtech, Sweden) Diluted with PBS containing FBS and added to the wells of the plates, respectively. This was reacted at room temperature for 2 hours, washed, and HRP-conjugated streptavidin was added to each well of the plate, and reacted at room temperature for 1 hour. The reaction mixture was washed with TMB coloring reagent and allowed to react until a clear spot was formed. After completion of the reaction, third distilled water was added to stop the reaction. Plates were washed several times with distilled water, dried at room temperature and the spots were calculated using an ELISPOT reader.
- splenocytes of mouse were dispensed at a density of 1.5 ⁇ 10 6 cells / well in a 96-well plate, and then the recombinant VZV gE antigen prepared in Example 1 was added thereto, And incubated for 48 hours in a 5% CO 2 incubator. The culture broth was transferred to each test group and centrifuged at 4 ° C and 3000 rpm for 5 minutes. The supernatant thus obtained was used as a sample for performing cytokine ELISA.
- the coating antibody contained in the Mouse IFN-? ELISA kit (BD, USA), Mouse IL-4 ELISA kit (BD, USA) and Mouse TNF-?
- IFN- ⁇ ELISPOT analysis showed that Lipo-Pam and poly (I: C) were prepared by mixing Lipo-Pam and L-pampo compared to G2 and G3, Induced overall generation of high IFN-y.
- the G6 group produced significantly higher IFN- ⁇ than the other test groups, and the G8 and G9 groups also produced relatively higher IFN- ⁇ .
- the G9 group to which the ultrasonic treatment was added before addition of the antigen produced significantly more IFN- ⁇ than the G7 group.
- IL-4 was highly produced in G6 group. Comparing the cellular immune response with the combination of Lipo-pam and poly (I: C), Lipo-pam did not have poly (I: C) (IFN-y) and IL-4 were produced in the G6 group administered with the vaccine prepared by mixing the poly (I: C) and poly (I: C).
- the results of ELISA analysis of IL-4 and TNF- ⁇ also showed similar trends with the results of ELISA analysis of IFN- ⁇ , and a large amount of IL-4 and TNF- ⁇ were induced in the G6 group.
- Lipo-pam did not have poly (I: C) 4b and TNF-a were secreted in the G6 group administered with the vaccine prepared by mixing the poly (I: C) and poly (I: C).
- the herpes zoster vaccine induces a cellular immune response as compared with the humoral immune response.
- the vaccine mixed with L-pampo in the liposome disperses and stabilizes the particle size of the mixture uniformly
- vaccines made by mixing Lipo-pam and poly (I: C) will maintain the size of the particles for a longer period of time with no additional steps . It was found effective to develop a vaccine formulation based on Lipo-Pam which induces cellular immune response better and has excellent stability of formulation.
- DC-Chol dimethylethancarbanoyl cholesterol
- DOPE dioleoyl-phosphatidylethanolamine
- Pam3-CSKKKK was used as 6-TAMRA
- SE 6-Carboxytetramethylrhodamine, succinimidyl ester
- VZV gE antigen was stained with fluorescein.
- Chol, DOPE and Pam3-CSKKKK were dissolved, and then DC-Chol and DOPE were mixed at a ratio of 3: 7 and Pam3-CSKKKK was added to the mixture at a concentration of 25 ⁇ g / dose.
- Lipo-Pam was prepared. Thereafter, the Lipo-Pam was mixed with poly (I: C) at a concentration of 40 / / dose, and the mixture was added with 5 / / dose of antigen to prepare a test vaccine. Respectively.
- the radius of the liposome lipid-stained dye was almost the same as that of the pigment stained with Pam3CSK.
- the dye coloration by the dye stained with the recombinant gE antigen of VZV The radius was larger than these.
- the prepared vaccine had a structure in which Pam3-CSKKKK and lipid form a liposome (Lipo-pam) and a recombinant gE antigen of VZV is bonded to the surface of the liposome (FIG. 5).
- the ratio of lipid, the capacity of Pam3-CSKKKK, the capacity of poly (I: C), and the immunogenicity of recombinant vaccine according to the degree of recombination of VZV gE antigen with liposomes were compared.
- DC-Chol, DOPE and Pam3-CSKKKK were dissolved and then DC-Chol and DOPE were mixed at a ratio of 1: 1 or 3: 7 and Pam3-CSKKKK was added thereto at a concentration of 25 or 100 / / Lipo-Pam was prepared in the same manner as in Example ⁇ 2-1>.
- poly (I: C) at a concentration of 20, 40, 60, 80 or 160 / / dose with Lipo-Pam as shown in Table 2 below
- a recombinant gE antigen of 5 / / dose of VZV was prepared.
- the prepared vaccine was intramuscularly injected into female C57BL / 6 mice at 6 weeks of age (Orient Bio, Korea) at 2-week intervals.
- mice were immunized at week 0, 2 weeks after the first vaccination and 2 weeks after the second vaccination, Of the serum was separated to prepare a sample. Using the prepared sample, the whole IgG antibody to the recombinant gE antigen of VZV was analyzed in the same manner as in Example ⁇ 2-2>.
- the ratio of DC-Chol: DOPE of Lipo-pam prepared by mixing the ratio of DC-Chol: DOPE of 3: 7 (G2 to G7) was 1: 1 (G8 to G12 ),
- the IgG antibody titer was higher than that of IgG antibody.
- the total IgG antibody level was highly induced in proportion to the capacity of the lipopeptides Pam3-CSKKKK and poly (I: C) (FIG. 6).
- G2, G5, G6, and G7 were found to bind most of the recombinant gE antigen of VZV to Lipo-pam.
- Example ⁇ 4-1 > In order to analyze the cellular immune response of the test vaccine administered in Example ⁇ 4-1 >, the spleen was removed from the mice at 4 weeks after the 2nd vaccination, 2-3>, ELISPOT assay and cytokine ELISA were performed to analyze the cellular immune response.
- the vaccine prepared with the ratio of DC-Chol: DOPE of 3: 7 showed a higher IFN- ⁇ ratio than the vaccine prepared with the ratio of DC-Chol: DOPE of 1: And IL-4.
- Pam3-CSKKKK was used at a concentration of 25 ⁇ g / dose
- IFN- ⁇ and IL-4 were most abundant when DC-Chol: DOPE was used at 3: 7
- poly (I: C) at 40 ⁇ g / IFN- ⁇ and IL-4 were produced as the concentration of poly (I: C) was higher when Pam3-CSKKKK was used at 100 ⁇ g / dose or 200 ⁇ g / dose, but Pam3-CSKKKK at 25 ⁇ g / dose IFN-y and IL-4 were significantly lower than those in the test group (Fig. 7A).
- cytokine ELISA analysis showed that the vaccine prepared with a ratio of DC-Chol: DOPE of 3: 7 was higher than that prepared with a ratio of DC-Chol: DOPE of 1: 1 More secretion of IFN- ⁇ and IL-4 was induced, whereas TNF- ⁇ was similar in two ratios. Similar to the ELISPOT results, the vaccine using Pam3-CSKKKK at 25 ⁇ g / dose induced more IFN- ⁇ , IL-4 and TNF- ⁇ secretion than the vaccine at 100 or 200 ⁇ g / dose.
- the ratio of DC-Chol: DOPE was 1: 1 in the G3 group using poly (I: C)
- the secretion of three cytokines was most induced in G8 group using poly (I: C) at 20 / / dose (Fig. 7B).
- Example 5 Lipids and Of VZV Recombination gE Comparison of immunogenicity of recombinant vaccine according to antigen dose
- the amount of recombinant gE antigen added to the lipid and VZV was determined by using DC-Chol: DOPE, 25 ⁇ g / dose of Pam3-CSKKKK and 20 ⁇ g / dose of poly (I: C) Were compared with the immunogenicity of the vaccine.
- mice were immunized at the 0th week after immunization, at 2 weeks after the first vaccination and at 2 weeks after the second vaccination, Of the serum was separated to prepare a sample. Using the prepared sample, the whole IgG antibody to the recombinant gE antigen of VZV was analyzed in the same manner as in Example ⁇ 2-2>.
- Example ⁇ 5-1 > In order to analyze the cellular immune response of the test vaccine administered in Example ⁇ 5-1 >, the spleen was removed from the mice at 4 weeks after the 2nd vaccination, 2-3>, ELISPOT assay and cytokine ELISA were performed to analyze the cellular immune response.
- ELISPOT analysis of IFN- ⁇ and IL-4 showed that recombinant gE antigen of VZV at a concentration of 2 ⁇ g / dose and DC-Chol: DOPE lipid at a concentration of 125 ⁇ g / IFN-y and IL-4 were most abundant in the G8 group (Fig. 9A).
- cytokine ELISA analysis showed that recombinant gE antigen of VZV at a concentration of 2 / / dose and G8 produced by using DC-Chol: DOPE lipid at a concentration of 125 ⁇ g / , Whereas the G11 group produced using DC-Chol and DOPC produced the least amount of cytokine secretion compared to the other test groups (FIG. 9b).
- Example ⁇ 6-1 > To evaluate the humoral immune response of the test vaccine administered in Example ⁇ 6-1 >, the mice were immunized at 0, 2, and 4 weeks after the first vaccination and 2 weeks after the second vaccination, And a sample was prepared. Using the prepared samples, the total IgG antibody to VZV gE antigen and the isotype of the antibody were analyzed in the same manner as in Example ⁇ 2-2>.
- Example ⁇ 6-1 > In order to analyze the cellular immune response of the test vaccine administered in Example ⁇ 6-1 >, spleen was removed from the mice at 4 weeks after the 2nd vaccination, 2-3>, ELISPOT assay and cytokine ELISA were performed to analyze the cellular immune response.
- IFN-? And IL-4 ELISPOT analysis showed that lipid was 125 ⁇ ⁇ / dose, poly (I: C) was 40 ⁇ ⁇ / dose and recombinant gE IFN-y and IL-4 were produced in the G6 group using the antigen at 2 / / dose (Fig. 11A).
- cytokine ELISA analysis showed that lipid was 125 / / dose, poly (I: C) was 40 ⁇ g / dose, and recombinant gE antigen of VZV was 2 ⁇ g / dose IFN-y, IL-4 and TNF-a were most secreted in G6 group (Fig. 11B).
- immunogenicity of the vaccine was compared according to the antigenic dose contained in the recombinant vaccine prepared using the attenuated live vaccine Zostavax and the recombinant VZV gE antigen.
- DC-Chol, DOPE and Pam3-CSKKKK, DC-Chol and DOPE mixed lipids were mixed at a ratio of 3: 7 at a concentration of 125 / / dose, and Pam3- CSKKKK at a concentration of 25 / / Lipo-Pam was prepared in the same manner as in Example ⁇ 2-1>, except that Chol, DOPE and Pam3-CSKKKK were mixed.
- L-pampo was also prepared by mixing 25 ⁇ g / dose of Pam3-CSKKKK, 200 ⁇ g / dose of poly (I: C) and 5 ⁇ g / dose of antigen and used as a control. Thereafter, test vaccines having compositions as described in Table 5 below were prepared.
- the prepared vaccine or crude Starbox was intramuscularly injected into 6-week-old C57BL / 6 female mice (Orient Bio, Korea) at 2-week intervals.
- mice were immunized at 0, 2, and 4 weeks after the first vaccination and 2 weeks after the second vaccination, Of the serum was separated to prepare a sample. Using the prepared samples, the total IgG antibody to the recombinant gE antigen of VZV and the isotype of the antibody were analyzed in the same manner as in Example ⁇ 2-2>.
- the G2 group administered with ZosterBox and the G3 group using aluminum hydroxide showed lower total IgG antibody than the G4, G5 and G6 groups using L-pampo or Lipo-Pam 12).
- the ratio of IgG2b / IgG1 to IgG2c / IgG1 was higher in the G4 group using L-pampo than in the G5 group using Lipo-pam Respectively.
- Example ⁇ 7-1 > To analyze the cellular immune response of the test vaccine administered in Example ⁇ 7-1 >, spleen was isolated from mice at 4 weeks after the second vaccination, to isolate whole splenocytes.
- ELISPOT assays and cytokine ELISA were performed using the spleen cells in the same manner as in Example ⁇ 2-3>, and the intracellular cytokine staining for IFN- ⁇ , TNF- ⁇ and IL-2 was performed using a flow cytometer (intracellular cytokine staining, ICS) analysis.
- Cellular immune responses were analyzed by comparing the degree of CD4 + T cells secreting cytokines specific for recombinant VZV gE antigen in each formulation.
- IFN- ⁇ and IL-4 ELISPOT analysis showed that the G2 group treated with Joostab had significantly lower IFN- ⁇ and IL-4, whereas G5 with Lipo-pam And G6 group produced the most IFN-y and IL-4 (Fig. 13A).
- cytokine ELISA analysis showed that the G2 group administered with Zostarbox induced the least secretion of IFN-y, IL-4 and TNF-alpha, while G5 with Lipo-pam And G6 group were the most induced secretion of IFN-y, IL-4 and TNF-a (Fig. 13B).
- cytokines secreted from each test group was high in the frequencies of CD4 + T cells secreting respective cytokines in the G5 and G6 groups using Lipo-pam (Fig. 14).
- Fig. 15 when comparing the polyfunctionality of gE antigen-specific CD4 + T cells, assuming that the number of cells that secrete one or more kinds of cytokines in each test group is 100% , And CD4 + T cells secreting one or more cytokines.
- the highest test group that secreted all three cytokines was the G5 and G6 groups using Lipo-pam.
- the ratio of CD4 + T cells secreting only one cytokine was high and it was confirmed that multifunctionality was low (Fig. 15).
- Example 8 Attenuated The lipid ratio of the shingles vaccine to the recombinant vaccine and Of poly (I: C) Comparison of immunogenicity by dose
- the immunogenicity of the vaccine according to the ratio of lipid contained in the recombinant vaccine prepared using the attenuated live vaccine Joostabox and recombinant gE antigen of VZV and poly (I: C) was compared .
- DC-Chol, DOPE and Pam3-CSKKKK were dissolved, and DC-Chol and DOPE were added to a concentration of 125 ⁇ g / dose in a ratio of 3: 7 such that the concentration of Pam3-CSKKKK was 25 ⁇ g / DPOL and Pam3-CSKKKK so that the concentration of Pam3-CSKKKK was 25 ⁇ g / dose such that DOPE and Pam3-CSKKKK were mixed or the lipid having a ratio of DC-Chol and DPPC of 125:
- Lipo-Pam was prepared in the same manner as in Example ⁇ 2-1 > L-pampo was also prepared by mixing 25 ⁇ g / dose of Pam3-CSKKKK, 200 ⁇ g / dose of poly (I: C) and 5 ⁇ g / dose of recombinant gE antigen of VZV.
- the DC-Chol DOPE liposome was prepared in the same manner as in Example ⁇ 2-1>. Thereafter, Lipo-Pam was mixed with poly (I: C) at a concentration of 20, 40 or 80 / / dose as shown in Table 6, and then 5 ⁇ g / dose of recombinant VZV gE antigen was added to the mixture (G10 and G11), L-pampo and DC-Chol: Lipo-Pam were simultaneously mixed with poly (I: C) and 5 ⁇ g / dose of recombinant VZV gE antigen DOPE liposomes were mixed (G5 group) or mixed with 5 ⁇ g / dose of recombinant VZV gE antigen (G2 group) in aluminum hydroxide at a concentration of 100 ⁇ g / dose to prepare a test vaccine. The prepared vaccine or Joostabox was intramuscularly injected twice at 6-week-old C57BL / 6 female mice (Orient Bio, Korea) at intervals of 2 weeks.
- mice were immunized at 0, 2, and 4 weeks after the first vaccination and 2 weeks after the second vaccination, Of the serum was separated to prepare a sample.
- Antibody specific antibody formation was analyzed by ELISA using the prepared samples to determine antibody titers.
- the whole IgG antibody to the recombinant gE antigen of VZV was analyzed in the same manner as in Example ⁇ 2-2>.
- the G3 group administered with crude starbox and the G2 group using aluminum hydroxide showed lower IgG antibody level than the G4 to G11 group using L-pampo or Lipo-Pam (Fig. 16 ).
- Example ⁇ 8-1 > In order to analyze the cellular immune response of the test vaccine administered in Example ⁇ 8-1 >, the spleen was removed from the mice at 4 weeks after the 2nd vaccination, 2-3>, ELISPOT assay and cytokine ELISA were performed to analyze the cellular immune response.
- IFN- ⁇ and IL-4 ELISPOT showed that IFN- ⁇ and IL-4 were significantly reduced in the G3 group treated with ZosterBox, while DC-Chol: DPPC (I: C) and 5 ⁇ g / dose of recombinant Lipo-pam at a concentration of 40 ⁇ g / dose were added to G7 and Lipo-Pam using 40 ⁇ g / And a large number of IFN-y and IL-4 were produced in the G11 group in which VZV gE antigen was simultaneously mixed (Fig. 17A).
- cytokine ELISA analysis showed that Lipo-pam prepared using DC-Chol: DPPC (1: 1) and G7 group using poly (I: C) at 40 / / DC-Chol: The highest secretion of IFN- ⁇ was induced in the G5 group mixed with DOPE liposome and L-pampo.
- IL-4 was not largely differentiated from the formulation, but many secretions were induced in the G7 to G9 and G11 groups using Lipo-pam prepared using DC-Chol: DPPC (1: 1). TNF- ⁇ was secreted in a large number in the G5, G7, G9 and G11 groups (Fig. 17B).
- Example 9 Types of lipids, Of poly (I: C) Capacity and Of VZV Recombination gE Comparison of Immunogenicity of Recombinant Vaccines by Mixing Agents
- DC-Chol, DOPE and Pam3-CSKKKK were dissolved, and DC-Chol and DOPE were added to a concentration of 125 ⁇ g / dose in a ratio of 3: 7 such that the concentration of Pam3-CSKKKK was 25 ⁇ g / DOPE and Pam3-CSKKKK or DC-Chol and DPPC such that the concentration of Pam3-CSKKKK was 25 ⁇ g / dose so that the concentration of lipid having a ratio of 1: 1 or 3: 7 of DC-Chol and DPPC was 125 ⁇ g / And Pam3-CSKKKK were mixed, Lipo-Pam was prepared in the same manner as in Example ⁇ 2-1>.
- L-pampo was also prepared by mixing 25 ⁇ g / dose of Pam3-CSKKKK, 200 ⁇ g / dose of poly (I: C) and 5 ⁇ g / dose of recombinant VZV gE antigen. Thereafter, Lipo-Pam and poly (I: C) at a concentration of 40 or 200 / / dose were mixed as shown in the following Table 7, and the mixture was further supplemented with 5 / / dose of recombinant VZV gE antigen (G3 to G6 ), Lipo-Pam and poly (I: C) at a concentration of 40 or 200 ⁇ g / dose and 5 ⁇ g / dose of recombinant VZV gE antigen simultaneously (G7 to G10 group).
- the prepared vaccine was intramuscularly injected into female C57BL / 6 mice at 6 weeks of age (Orient Bio, Korea) at 2-week intervals.
- Example ⁇ 9-1 > To analyze the humoral immune response of the test vaccine administered in Example ⁇ 9-1 >, the mice were immunized at 0, 2, and 4 weeks after the first vaccination and 2 weeks after the second vaccination And a sample was prepared. Using the prepared sample, the whole IgG antibody to the recombinant gE antigen of VZV was analyzed in the same manner as in Example ⁇ 2-2>.
- Example ⁇ 9-1 > In order to analyze the cellular immune response of the test vaccine administered in Example ⁇ 9-1 >, splenic cells were isolated from the mice at 4 weeks after the 2nd vaccination, 2-3>, ELISPOT assay and cytokine ELISA were performed to analyze the cellular immune response.
- cytokine ELISA analysis showed that the secretion of IFN-? And TNF-? was induced more in the formulation using DC-Chol: DPPC than in the formulation using DC-Chol: DOPE, The highest secretion of IFN- ⁇ and TNF- ⁇ was induced in the G6 and G10 groups, in which the ratio of -Chol: DPPC was 1: 1.
- IL-4 was more secreted in the G6 and G10 groups using the ratio of G2 and DC-Chol: DPPC using L-pampo at a ratio of 1: 1, compared with other formulations, and G3 with DC-Chol: DOPE
- secretion of IL-4 was induced to a degree similar to that of the formulation using DC-Chol: DPPC (Fig. 19B).
- Example 10 Types and amounts of lipids, types of immunologically active substances, and Of VZV Recombination gE Comparison of immunogenicity of recombinant vaccine according to antigen dose
- DC-Chol and DOPE were added at a concentration of 3: 7 lipid to a concentration of 125 / / dose, and Pam3-CSKKKK to a concentration of 25 / / Chol, DOPE and Pam3-CSKKKK, or a mixture of DC-Chol and DPPC such that Pam3-CSKKKK is at a concentration of 25 ⁇ g / dose such that lipid having a ratio of 1: 1 of DC-Chol and DPPC is 62.5, 125 or 250 ⁇ g / , DPPC and Pam3-CSKKKK were mixed, Lipo-Pam was prepared in the same manner as in Example ⁇ 2-1>.
- a test vaccine was prepared by adding 5 ⁇ g / dose of recombinant VZV gE antigen to the mixture.
- the prepared vaccine was intramuscularly injected into female C57BL / 6 mice at 6 weeks of age (Orient Bio, Korea) at 2-week intervals.
- Example ⁇ 10-1 > To evaluate the humoral immune response of the test vaccine administered in Example ⁇ 10-1 >, the mice were immunized at 0, 2, and 4 weeks after the first vaccination and 2 weeks after the second vaccination, And a sample was prepared. Using the prepared sample, the whole IgG antibody to the recombinant gE antigen of VZV was analyzed in the same manner as in Example ⁇ 2-2>.
- the total antibody titer according to the type of lipid was highest in the G2 group using Lipo-pam prepared by using the lipids of DC-Chol and DOPE, : C) High antibody formation was also induced in G9 group using QS21 instead (Fig. 20).
- Example ⁇ 10-1 > In order to analyze the cellular immune response of the test vaccine administered in Example ⁇ 10-1 >, the spleen was removed from the mouse at the 4th week after the second vaccination, 2-3>, ELISPOT assay and cytokine ELISA were performed to analyze the cellular immune response.
- IFN-y ELISPOT results showed that IFN-y was produced in the test group using DC-Chol and DPPC as lipids as compared with the G2 group using DC-Chol and DOPE as lipids, Lipo-pam, which was prepared by using DC-Chol and DPPC as lipid, and IFN- ⁇ , which was obtained by mixing QS21 as an immunoreactive substance, were produced in the G9 group.
- IL-4 ELISPOT results showed that more IL-4 was produced in the test group using DC-Chol and DPPC as lipids compared to the G2 group using DC-Chol and DOPE as lipids, and 40 ⁇ g
- the G6 group which was mixed with poly (I: C) / dose 5 ⁇ g / dose of recombinant VZV gE antigen
- cytokine ELISA analysis showed that more IFN-?, IL-4 and? -GHP in the G3 to G8 group using DC-Chol: DPPC than in the G2 group using DC-Chol: Secretion of TNF- ⁇ was induced.
- G6 group with 40 ⁇ g / dose poly (I: C) and 5 ⁇ g / dose recombinant VZV gE antigen, 5 ⁇ g / dose QS21 and 5 ⁇ g / dose recombinant VZV gE The secretion of IFN- ⁇ and TNF- ⁇ in the G9 group mixed with the antigen was higher in the G9 group and the secretion of IL-4 was induced to a similar level (FIG. 21b).
- the immunogenicity of the vaccine according to the type of lipopeptide contained in the recombinant vaccine prepared using recombinant gE antigen of VZV was compared.
- Lipo-Pam was prepared in the same manner as in Example ⁇ 2-1> except that lipopeptide was mixed, and the size and zeta potential of Lipo-Pam were measured using a particle size analyzer (Malvern, Nono-ZS) Respectively.
- a test vaccine was prepared by mixing Lipo-Pam and poly (I: C) at a concentration of 40 ⁇ g / dose, and then adding 5 ⁇ g / dose of recombinant gE antigen of VZV to the mixture.
- Nono-ZS was used to measure the size and zeta potential of the test vaccine composition.
- the size and zeta potential of the recombinant vaccine according to the type of lipopeptide The lipopeptides used in vaccine manufacture Size (nm) Particle distribution (PDI) Zeta potential (mV) Pam3-CSKKKK + poly (I: C) + antigen 211.9 0.191 -53.7 Dhc-SKKKK + poly (I: C) + antigen 128.0 0.163 -38.8 PamDhc-SKKKK + poly (I: C) + antigen 180.5 0.156 -28.5 Pam-CSKKKK + poly (I: C) + antigen 207.8 0.182 -30.2 Pam2Cys-SKKKK + poly (I: C) + antigen 138.6 0.180 -34.5 PHC-SKKKK + poly (I: C) + antigen 122.2 0.178 -35.0 FSL-1 + poly (I: C) + antigen 276.0 0.273 -35.2
- Lipo-Pam produced a recombinant vaccine properly without sediment, which was 90-130 nm in size (Table 9).
- vaccine compositions containing lipopeptides, poly (I: C) and antigens formed recombinant vaccines at sizes of 120-300 nm (Table 10).
- the vaccine prepared above was intramuscularly injected twice at 6-week-old C57BL / 6 female mice (Orient Bio, Korea) at intervals of 2 weeks as shown in Table 11 below.
- mice were immunized at week 0, 2 weeks after the first immunization, 2 weeks after the second vaccination, Of the serum was separated to prepare a sample. Using the prepared sample, the whole IgG antibody to the recombinant gE antigen of VZV was analyzed in the same manner as in Example ⁇ 2-2>.
- Example ⁇ 11-1 > In order to analyze the cellular immune response of the test vaccine administered in Example ⁇ 11-1 >, splenic cells were isolated from the mice at 4 weeks after the second vaccination, 2-3>, ELISPOT assay and cytokine ELISA were performed to analyze the cellular immune response.
- IFN-? ELISPOT resulted in the generation of antibodies in all the test groups.
- antibodies to G3, G4, and G4 using Pam3-CSKKKK, Dhc- SKKKK, Pam-CSKKKK, or PHC- SKKKK as lipopeptides IFN- ⁇ was well produced in the G6 and G8 groups.
- IL-4 ELISPOT produced IL-4 well in G3, G4, G7 and G8 groups using Pam3-CSKKKK, Dhc-SKKKK, Pam2Cys-SKKKK or PHC-SKKKK as lipopeptides (Fig. 23A).
- cytokine ELISA analysis revealed that the secretion of IFN-y, IL-4 and TNF- alpha was induced more in the G3 and G4 groups using Pam3-CSKKKK or Dhc-SKKKK as the lipopeptide .
- Example 11 it can be seen that, in the production of Lipo-pam, the humoral and cellular immune responses are induced even when any kind of lipopeptide is used, whereby the Lipo-pam according to the present invention, Peptide combinations of the present invention.
- the efficacy of the vaccine can be improved by using Pam3-CSKKKK, which induces both humoral and cellular immune responses, as a lipopeptide.
- Example 12 L- pampo or Lipo - with pam Of the formulated recombinant vaccine Japanese encephalitis Comparison of immunogenicity of virus against gE antigen
- DC-Chol, DOPE and Pam3-CSKKKK were dissolved, and DC-Chol and DOPE were added to a concentration of 125 ⁇ g / dose in a ratio of 3: 7 such that the concentration of Pam3-CSKKKK was 25 ⁇ g / Lipo-Pam was prepared in the same manner as in Example ⁇ 2-1>, except that DOPE and Pam3-CSKKKK were mixed.
- L-pampo was also prepared by mixing 25 ⁇ g / dose of Pam3-CSKKKK, 20 ⁇ g / dose of poly (I: C), and 0.1 or 0.5 ⁇ g / dose of recombinant JEV gE antigen.
- the recombinant JEV gE antigen was expressed in a baculovirus-insect cell system and purified. Thereafter, Lipo-Pam and poly (I: C) at a concentration of 40 / / dose were mixed as shown in Table 12, and then 0.1 or 0.5 / / dose of recombinant JEV gE antigen was added to the mixture to prepare a test vaccine Respectively.
- the prepared vaccine was intramuscularly injected twice at 6-week-old BALB / c mouse female (Orient Bio, Korea) at intervals of 2 weeks.
- mice were immunized at the 0th week after immunization, at the 2nd week after the first vaccination and at the second week after the second vaccination, Of the serum was separated to prepare a sample.
- the whole IgG antibody to the JEV gE antigen using the prepared sample was prepared in the same manner as in Example ⁇ 2-2 > except that the recombinant JEV gE antigen or the inactivated JEV antigen was coated on a 96-well microplate at a concentration of 100 ng / Were analyzed in the same manner.
- the total IgG antibody against the recombinant JEV gE antigen (FIG. 24A) and the total IgG antibody against the inactivated JEV antigen (FIG. 24B) contained 0.5 ⁇ g / dose of antigen And the highest in the Lipo-pam formulation (G7 group) used.
- Isotype analysis of antibodies against recombinant JEV gE antigens showed that IgG1 antibody titers were highest in the G5 group using L-pampo when 0.5 ⁇ g / dose of antigen was used, and IgG2a and IgG2b antibody titers And the highest in the G7 group using Lipo-pam.
- Example ⁇ 12-1 > In order to analyze the cellular immune response of the test vaccine administered in Example ⁇ 12-1 >, splenic cells were isolated from the mice at 4 weeks after the second vaccination, and then splenic cells were isolated and then the recombinant JEV gE ELISPOT assay and cytokine ELISA were performed in the same manner as in Example ⁇ 2-3 > except that the antigen or the inactivated JEV antigen was used to analyze the cellular immune response.
- IFN-y and IL-4 ELISPOT resulted in the highest production of IFN-y and IL-4 in the Lipo-pam formulations G6 and G7 (Fig. 25A).
- cytokine ELISA analysis showed that both IFN-y, IL-4 and TNF-a were in the Lipo-pam formulations (G6 and G7), L-pampo formulations (G4 and G5) Secretion was induced in the order of inactivated vaccine (G2, G3 group) (Fig. 25B).
- Lipo-pam as an immunity enhancer in the preparation of a recombinant Japanese encephalitis vaccine helps to improve the efficacy of vaccine by inducing humoral and cellular immune responses well , Indicating that Lipo-pam has immune-enhancing activity against various antigens.
- Example 13 Alum ( alum ), L- pampo or Lipo - with pam Immunogenicity of seasonal inactivated influenza virus antigens in formulated vaccines
- lipids with a ratio of 3: 7 of DC-Chol and DOPE or lipids with a ratio of DC: Chol and DPPC of 1: Lipo-pam was prepared in the same manner as in Example ⁇ 2-1> except that DC-Chol, DOPE, DPPC and Pam3-CSKKKK were mixed so that the concentration of Pam3-CSKKKK was 25 ⁇ g / dose.
- L-pampo contained 0.5 ⁇ g / strain / dose of seasonal inactivated influenza virus antigen at 25 ⁇ g / dose of Pam3-CSKKKK, 20 ⁇ g / dose of poly (I: C), and 4 strains .
- the seasonal inactivated influenza virus antigens of the four strains were identified as A / California / 07/2009 (H1N1), A / Hong Kong / 4801/2014 (H3N2), B / nostri / 3073/2013 (BY) or B / Brisbane / These antigens were amplified in eggs, purified and used after production. Thereafter, Lipo-pam and poly (I: C) at a concentration of 40 / / dose were mixed as shown in Table 13 below, and 0.5 ⁇ g / strain / dose of seasonal inactivated influenza virus antigen was further added to the mixture, .
- the prepared vaccine was intramuscularly injected twice at 6-week-old BALB / c mouse female (Orient Bio, Korea) at intervals of 2 weeks.
- mice were immunized at the 0th week after immunization, at the 2nd week after the first vaccination and at the second week after the second vaccination, Of the serum was separated to prepare a sample. Using the prepared samples, the total IgG antibody to the seasonal inactivated influenza virus antigens was sequenced except for the seasonal inactivated influenza virus antigens of four strains were coated at a concentration of 25 ng / well in a 96-well microplate, respectively.
- the total IgG antibody titer against the seasonal inactivated influenza virus antigen was the highest in the L-pampo formulations (G4 group) in all four strains, but the Lipo-pam formulations G5 and G6 (G6 group) in which 1: 1 ratio of DC-Chol and DPPC was included, showed high IgG antibody titer.
- the total IgG antibody titer of the test group (G3 group) using alum alone (G2 group) and alum as an immunity enhancer was significantly lower than that of Lipo-pam (Fig. 26).
- Example ⁇ 13-1 > In order to analyze the cellular immune response of the test vaccine administered in Example ⁇ 13-1 >, the spleen was removed from the mouse at the 4th week after the 2nd vaccination, ELISPOT assays and cytokine ELISA were performed in the same manner as in Example ⁇ 2-3 > except that the seasonal inactivated influenza virus antigens were used.
- IFN-gamma ELISPOT resulted in the highest production of IFN-y for seasonal inactivated influenza virus antigens of four strains in the Lipo-pam formulations G5 and G6 ).
- IL-4 ELISPOT revealed that IL-4 was also secreted in G5 and G6 groups, which are lower than the formulations (G2 and G3) in which the antigen alone or alum was added, but Lipo-pam formulations (Fig. 28) .
- cytokine ELISA analysis showed that IFN-? And TNF-? Were produced in the Lipo-pam formulations G5 and G6 (FIGS. 29 and 30) Was lower than that of the added formulations (G2 and G3) but secreted IL-4 (Fig. 31).
- Lipo-pam as an adjuvant in the preparation of a seasonal inactivated influenza vaccine can improve vaccine efficacy by inducing both humoral and cellular immune responses
- Lipo-pam a vaccine adjuvant according to the present invention, can be used together with various kinds of antigens without being limited to the kinds of antigens.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
도 21b는 지질의 종류와 용량, 면역활성물질의 종류 및 VZV의 재조합 gE 항원 용량에 따른 재조합 백신의 VZV의 재조합 gE 항원에 대한 IFN-γ, IL-4 및 TNF-α의 ELISA 분석 결과를 비교한 그래프이다.
시험군 | 조성 |
G1 | PBS |
G2 | 리포좀(DC-Chol:DOPE(3:7) 125 ㎍)+L-Pampo(Pam3-CSKKKK 25 ㎍+폴리(I:C) 20 ㎍)+항원 5 ㎍/초음파처리 |
G3 | 리포좀(DC-Chol:DOPE(3:7) 125 ㎍)+L-Pampo(Pam3-CSKKKK 25 ㎍+폴리(I:C) 200 ㎍)+항원 5 ㎍ |
G4 | 리포좀(DC-Chol:DOPE(3:7) 125 ㎍)+폴리(I:C) 20 ㎍+항원 5 ㎍ |
G5 | Lipo-Pam(DC-Chol:DOPE(3:7) 125 ㎍+Pam3-CSKKKK 25 ㎍)+항원 5 ㎍/초음파처리 |
G6 | Lipo-Pam(DC-Chol:DOPE(3:7) 125 ㎍+Pam3-CSKKKK 25 ㎍)+폴리(I:C) 20 ㎍+항원 5 ㎍ |
G7 | Lipo-Pam(DC-Chol:DOPE(3:7) 125 ㎍+Pam3-CSKKKK 25 ㎍)+폴리(I:C) 200 ㎍+항원 5 ㎍ |
G8 | Lipo-Pam(DC-Chol:DOPE(3:7) 125 ㎍+Pam3-CSKKKK 100 ㎍)+폴리(I:C) 200 ㎍+항원 5 ㎍ |
G9 | Lipo-Pam(DC-Chol:DOPE(3:7) 125 ㎍+Pam3-CSKKKK 25 ㎍)+폴리(I:C) 200 ㎍/초음파처리+항원 5 ㎍ |
시험군 | 조성 |
G1 | PBS |
G2 | Lipo-pam(DC-Chol:DOPE(3:7) 125 ㎍+Pam3-CSKKKK 25 ㎍)+폴리(I:C) 20 ㎍+항원 5 ㎍ |
G3 | Lipo-pam(DC-Chol:DOPE(3:7) 125 ㎍+Pam3-CSKKKK 25 ㎍)+폴리(I:C) 40 ㎍+항원 5 ㎍ |
G4 | Lipo-pam(DC-Chol:DOPE(3:7) 125 ㎍+Pam3-CSKKKK 25 ㎍)+폴리(I:C) 80 ㎍+항원 5 ㎍ |
G5 | Lipo-pam(DC-Chol:DOPE(3:7) 125 ㎍+Pam3-CSKKKK 100 ㎍)+폴리(I:C) 60 ㎍+항원 5 ㎍ |
G6 | Lipo-pam(DC-Chol:DOPE(3:7) 125 ㎍+Pam3-CSKKKK 100 ㎍)+폴리(I:C) 80 ㎍+항원 5 ㎍ |
G7 | Lipo-pam(DC-Chol:DOPE(3:7) 125 ㎍+Pam3-CSKKKK 200 ㎍)+폴리(I:C) 160 ㎍+항원 5 ㎍ |
G8 | Lipo-pam(DC-Chol:DOPE(1:1) 125 ㎍+Pam3-CSKKKK 25 ㎍)+폴리(I:C) 20 ㎍+항원 5 ㎍ |
G9 | Lipo-pam(DC-Chol:DOPE(1:1) 125 ㎍+Pam3-CSKKKK 25 ㎍)+폴리(I:C) 40 ㎍+항원 5 ㎍ |
G10 | Lipo-pam(DC-Chol:DOPE(1:1) 125 ㎍+Pam3-CSKKKK 25 ㎍)+폴리(I:C) 80 ㎍+항원 5 ㎍ |
G11 | Lipo-pam(DC-Chol:DOPE(1:1) 125 ㎍+Pam3-CSKKKK 100 ㎍)+폴리(I:C) 60 ㎍+항원 5 ㎍ |
G12 | Lipo-pam(DC-Chol:DOPE(1:1) 125 ㎍+Pam3-CSKKKK 100 ㎍)+폴리(I:C) 80 ㎍+항원 5 ㎍ |
시험군 | 조성 |
G1 | PBS |
G2 | Lipo-pam(DC-Chol:DOPE(3:7) 31.25 ㎍+Pam3-CSKKKK 25 ㎍)+폴리(I:C) 20 ㎍+항원 2 ㎍ |
G3 | Lipo-pam(DC-Chol:DOPE(3:7) 31.25 ㎍+Pam3-CSKKKK 25 ㎍)+폴리(I:C) 20 ㎍+항원 5 ㎍ |
G4 | Lipo-pam(DC-Chol:DOPE(3:7) 31.25 ㎍+Pam3-CSKKKK 25 ㎍)+폴리(I:C) 20 ㎍+항원 10 ㎍ |
G5 | Lipo-pam(DC-Chol:DOPE(3:7) 62.5 ㎍+Pam3-CSKKKK 25 ㎍)+폴리(I:C) 20 ㎍+항원 2 ㎍ |
G6 | Lipo-pam(DC-Chol:DOPE(3:7) 62.5 ㎍+Pam3-CSKKKK 25 ㎍)+폴리(I:C) 20 ㎍+항원 5 ㎍ |
G7 | Lipo-pam(DC-Chol:DOPE(3:7) 62.5 ㎍+Pam3-CSKKKK 25 ㎍)+폴리(I:C) 20 ㎍+항원 10 ㎍ |
G8 | Lipo-pam(DC-Chol:DOPE(3:7) 125 ㎍+Pam3-CSKKKK 25 ㎍)+폴리(I:C) 20 ㎍+항원 2 ㎍ |
G9 | Lipo-pam(DC-Chol:DOPE(3:7) 125 ㎍+Pam3-CSKKKK 25 ㎍)+폴리(I:C) 20 ㎍+항원 5 ㎍ |
G10 | Lipo-pam(DC-Chol:DOPE(3:7) 125 ㎍+Pam3-CSKKKK 25 ㎍)+폴리(I:C) 20 ㎍+항원 10 ㎍ |
G11 | Lipo-pam(DC-Chol:DOPC(3:7) 125 ㎍+Pam3-CSKKKK 25 ㎍)+폴리(I:C) 20 ㎍+항원 5 ㎍ |
시험군 | 조성 |
G1 | PBS |
G2 | Lipo-pam(DC-Chol:DOPE(3:7) 62.5 ㎍+Pam3-CSKKKK 25 ㎍)+폴리(I:C) 20 ㎍+항원 2 ㎍ |
G3 | Lipo-pam(DC-Chol:DOPE(3:7) 62.5 ㎍+Pam3-CSKKKK 25 ㎍)+폴리(I:C) 20 ㎍+항원 5 ㎍ |
G4 | Lipo-pam(DC-Chol:DOPE(3:7) 125 ㎍+Pam3-CSKKKK 25 ㎍)+폴리(I:C) 20 ㎍+항원 2 ㎍ |
G5 | Lipo-pam(DC-Chol:DOPE(3:7) 125 ㎍+Pam3-CSKKKK 25 ㎍)+폴리(I:C) 20 ㎍+항원 5 ㎍ |
G6 | Lipo-pam(DC-Chol:DOPE(3:7) 125 ㎍+Pam3-CSKKKK 25 ㎍)+폴리(I:C) 40 ㎍+항원 2 ㎍ |
G7 | Lipo-pam(DC-Chol:DOPE(3:7) 125 ㎍+Pam3-CSKKKK 25 ㎍)+폴리(I:C) 40 ㎍+항원 5 ㎍ |
G8 | Lipo-pam(DC-Chol:DOPE(3:7) 250 ㎍+Pam3-CSKKKK 25 ㎍)+폴리(I:C) 80 ㎍+항원 2 ㎍ |
G9 | Lipo-pam(DC-Chol:DOPE(3:7) 250 ㎍+Pam3-CSKKKK 25 ㎍)+폴리(I:C) 80 ㎍+항원 5 ㎍ |
G10 | Lipo-pam(DC-Chol:DOPE(3:7) 250 ㎍+Pam3-CSKKKK 25 ㎍)+폴리(I:C) 80 ㎍+항원 10 ㎍ |
G11 | Lipo-pam(DC-Chol:DOPE(3:7) 250 ㎍+Pam3-CSKKKK 25 ㎍)+폴리(I:C) 100 ㎍+항원 5 ㎍ |
시험군 | 조성 |
G1 | PBS |
G2 | 조스타박스(약독수두생바이러스 1940 PFU, 사람에 투여하는 양의 1/10) |
G3 | 수산화알루미늄 100 ㎍+항원 5 ㎍ |
G4 | L-Pampo(Pam3-CSKKKK 25 ㎍+폴리(I:C) 200 ㎍)+항원 5 ㎍ |
G5 | Lipo-pam(DC-Chol:DOPE(3:7) 125 ㎍+Pam3-CSKKKK 25 ㎍)+폴리(I:C) 40 ㎍+항원 2 ㎍ |
G6 | Lipo-pam(DC-Chol:DOPE(3:7) 125 ㎍+Pam3-CSKKKK 25 ㎍)+폴리(I:C) 40 ㎍+항원 5 ㎍ |
시험군 | 조성 |
G1 | PBS |
G2 | 수산화알루미늄 100 ㎍+항원 5 ㎍ |
G3 | 조스타박스(약독수두생바이러스 1940 PFU, 사람에 투여하는 양의 1/10) |
G4 | L-Pampo(Pam3-CSKKKK 25 ㎍+폴리(I:C) 200 ㎍)+항원 5 ㎍ |
G5 | 리포좀(DC-Chol:DOPE(3:7) 125 ㎍)+L-Pampo(Pam3-CSKKKK 25 ㎍+폴리(I:C) 200 ㎍)+항원 5 ㎍/초음파처리 |
G6 | Lipo-pam(DC-Chol:DOPE(3:7) 125 ㎍+Pam3-CSKKKK 25 ㎍)+폴리(I:C) 40 ㎍+항원 5 ㎍ |
G7 | Lipo-pam(DC-Chol:DPPC(1:1) 125 ㎍+Pam3-CSKKKK 25 ㎍)+폴리(I:C) 40 ㎍+항원 5 ㎍ |
G8 | Lipo-pam(DC-Chol:DPPC(1:1) 125 ㎍+Pam3-CSKKKK 25 ㎍)+폴리(I:C) 20 ㎍+항원 5 ㎍ |
G9 | Lipo-pam(DC-Chol:DOPE(1:1) 125 ㎍+Pam3-CSKKKK 25 ㎍)+폴리(I:C) 80 ㎍+항원 5 ㎍ |
G10 | Lipo-pam(DC-Chol:DOPE(3:7) 125 ㎍+Pam3-CSKKKK 25 ㎍)+[폴리(I:C) 40 ㎍+항원 5 ㎍] |
G11 | Lipo-pam(DC-Chol:DOPE(1:1) 125 ㎍+Pam3-CSKKKK 25 ㎍)+[폴리(I:C) 40 ㎍+항원 5 ㎍] |
시험군 | 조성 |
G1 | PBS |
G2 | L-Pampo(Pam3-CSKKKK 25 ㎍+폴리(I:C) 200 ㎍)+항원 5 ㎍ |
G3 | Lipo-pam(DC-Chol:DOPE(3:7) 125 ㎍+Pam3-CSKKKK 25 ㎍)+폴리(I:C) 40 ㎍+항원 5 ㎍ |
G4 | Lipo-pam(DC-Chol:DPPC(3:7) 125 ㎍+Pam3-CSKKKK 25 ㎍)+폴리(I:C) 40 ㎍+항원 5 ㎍ |
G5 | Lipo-pam(DC-Chol:DPPC(3:7) 125 ㎍+Pam3-CSKKKK 25 ㎍)+폴리(I:C) 200 ㎍+항원 5 ㎍ |
G6 | Lipo-pam(DC-Chol:DPPC(1:1) 125 ㎍+Pam3-CSKKKK 25 ㎍)+폴리(I:C) 40 ㎍+항원 5 ㎍ |
G7 | Lipo-pam(DC-Chol:DOPE(3:7) 125 ㎍+Pam3-CSKKKK 25 ㎍)+[폴리(I:C) 40 ㎍+항원 5 ㎍] |
G8 | Lipo-pam(DC-Chol:DPPC(3:7) 125 ㎍+Pam3-CSKKKK 25 ㎍)+[폴리(I:C) 40 ㎍+항원 5 ㎍] |
G9 | Lipo-pam(DC-Chol:DPPC(3:7) 125 ㎍+Pam3-CSKKKK 25 ㎍)+[폴리(I:C) 200 ㎍+항원 5 ㎍] |
G10 | Lipo-pam(DC-Chol:DPPC(1:1) 125 ㎍+Pam3-CSKKKK 25 ㎍)+[폴리(I:C) 40 ㎍+항원 5 ㎍] |
시험군 | 조성 |
G1 | PBS |
G2 | Lipo-pam(DC-Chol:DOPE(3:7) 125 ㎍+Pam3-CSKKKK 25 ㎍)+폴리(I:C) 40 ㎍+항원 5 ㎍ |
G3 | Lipo-pam(DC-Chol:DPPC(1:1) 62.5 ㎍+Pam3-CSKKKK 25 ㎍)+폴리(I:C) 40 ㎍+항원 2 ㎍ |
G4 | Lipo-pam(DC-Chol:DPPC(1:1) 62.5 ㎍+Pam3-CSKKKK 25 ㎍)+폴리(I:C) 40 ㎍+항원 5 ㎍ |
G5 | Lipo-pam(DC-Chol:DPPC(1:1) 125 ㎍+Pam3-CSKKKK 25 ㎍)+폴리(I:C) 40 ㎍+항원 2 ㎍ |
G6 | Lipo-pam(DC-Chol:DPPC(1:1) 125 ㎍+Pam3-CSKKKK 25 ㎍)+폴리(I:C) 40 ㎍+항원 5 ㎍ |
G7 | Lipo-pam(DC-Chol:DPPC(1:1) 250 ㎍+Pam3-CSKKKK 25 ㎍)+폴리(I:C) 40 ㎍+항원 2 ㎍ |
G8 | Lipo-pam(DC-Chol:DPPC(1:1) 250 ㎍+Pam3-CSKKKK 25 ㎍)+폴리(I:C) 40 ㎍+항원 5 ㎍ |
G9 | Lipo-pam(DC-Chol:DPPC(1:1) 125 ㎍+Pam3-CSKKKK 25 ㎍)+QS21 5 ㎍+항원 5 ㎍ |
Lipo-Pam에 삽입된 리포펩티드 | 크기(nm) | 입자의 분포도(PDI) | 제타포텐셜(mV) |
Pam3-CSKKKK | 96.49 | 0.1465 | 27.2 |
Dhc-SKKKK | 116.4 | 0.217 | 56.1 |
PamDhc-SKKKK | 98.46 | 0.218 | 59.1 |
Pam-CSKKKK | 89.05 | 0.151 | 42.9 |
Pam2Cys-SKKKK | 97.74 | 0.222 | 54.4 |
PHC-SKKKK | 95.96 | 0.206 | 50.3 |
FSL-1 | 125.9 | 0.168 | 37.8 |
백신 제조에 사용된 리포펩티드 | 크기(nm) | 입자의 분포도(PDI) | 제타포텐셜(mV) |
Pam3-CSKKKK+폴리(I:C)+항원 | 211.9 | 0.191 | -53.7 |
Dhc-SKKKK+폴리(I:C)+항원 | 128.0 | 0.163 | -38.8 |
PamDhc-SKKKK+폴리(I:C)+항원 | 180.5 | 0.156 | -28.5 |
Pam-CSKKKK+폴리(I:C)+항원 | 207.8 | 0.182 | -30.2 |
Pam2Cys-SKKKK+폴리(I:C)+항원 | 138.6 | 0.180 | -34.5 |
PHC-SKKKK+폴리(I:C)+항원 | 122.2 | 0.178 | -35.0 |
FSL-1+폴리(I:C)+항원 | 276.0 | 0.273 | -35.2 |
시험군 | 조성 |
G1 | PBS |
G2 | 조스타박스(약독수두생바이러스 1940 PFU, 사람에 투여하는 양의 1/10) |
G3 | Lipo-pam(DC-Chol:DPPC(1:1) 125 ㎍+Pam3-CSKKKK 25 ㎍)+폴리(I:C) 40 ㎍+항원 5 ㎍ |
G4 | Lipo-pam(DC-Chol:DPPC(1:1) 125 ㎍+Dhc-SKKKK 25 ㎍)+폴리(I:C) 40 ㎍+항원 5 ㎍ |
G5 | Lipo-pam(DC-Chol:DPPC(1:1) 125 ㎍+PamDhc-SKKKK 25 ㎍)+폴리(I:C) 40 ㎍+항원 5 ㎍ |
G6 | Lipo-pam(DC-Chol:DPPC(1:1) 125 ㎍+Pam-CSKKKK 25 ㎍)+폴리(I:C) 40 ㎍+항원 5 ㎍ |
G7 | Lipo-pam(DC-Chol:DPPC(1:1) 125 ㎍+Pam2Cys-SKKKK 25 ㎍)+폴리(I:C) 40 ㎍+항원 5 ㎍ |
G8 | Lipo-pam(DC-Chol:DPPC(1:1) 125 ㎍+PHC-SKKKK 25 ㎍)+폴리(I:C) 40 ㎍+항원 5 ㎍ |
G9 | Lipo-pam(DC-Chol:DPPC(1:1) 125 ㎍+FSL-1 25 ㎍)+폴리(I:C) 40 ㎍+항원 5 ㎍ |
시험군 | 조성 |
G1 | PBS |
G2 | 불활성화된 JEV 항원 0.1 ㎍/dose |
G3 | 불활성화된 JEV 항원 0.5 ㎍/dose |
G4 | L-Pampo(Pam3-CSKKKK 25 ㎍+폴리(I:C) 20 ㎍)+재조합 JEV gE 항원 0.1 ㎍ |
G5 | L-Pampo(Pam3-CSKKKK 25 ㎍+폴리(I:C) 20 ㎍)+재조합 JEV gE 항원 0.5 ㎍ |
G6 | Lipo-pam(DC-Chol:DOPE(3:7) 125 ㎍+Pam3-CSKKKK 25 ㎍)+폴리(I:C) 40 ㎍+재조합 JEV gE 항원 0.1 ㎍ |
G7 | Lipo-pam(DC-Chol:DOPE(3:7) 125 ㎍+Pam3-CSKKKK 25 ㎍)+폴리(I:C) 40 ㎍+재조합 JEV gE 항원 0.5 ㎍ |
시험군 | 조성 |
G1 | PBS |
G2 | 계절형 불활화 독감 바이러스 항원 0.5 ㎍/strain |
G3 | 알룸+계절형 불활화 독감 바이러스 항원 0.5 ㎍/strain |
G4 | L-Pampo(Pam3-CSKKKK 25 ㎍+폴리(I:C) 20 ㎍)+계절형 불활화 독감 바이러스 항원 0.5 ㎍/strain |
G5 | Lipo-pam(DC-Chol:DOPE(3:7) 125 ㎍+Pam3-CSKKKK 25 ㎍)+폴리(I:C) 40 ㎍+계절형 불활화 독감 바이러스 항원 0.5 ㎍/strain |
G6 | Lipo-pam(DC-Chol:DPPC(1:1) 125 ㎍+Pam3-CSKKKK 25 ㎍)+폴리(I:C) 40 ㎍+계절형 불활화 독감 바이러스 항원 0.5 ㎍/strain |
Claims (17)
- 리포펩티드가 삽입된 리포좀(liposome)을 유효성분으로 포함하는 백신 아쥬반트(adjuvant).
- 제1항에 있어서, 상기 리포펩티드가 Pam3Cys-SKKKK, Pam3-CSKKKK, PHC-SKKKK, Ole2PamCys-SKKKK, Pam2Cys-SKKKK, PamCys(Pam)-SKKKK, Ole2Cys-SKKKK, Myr2Cys-SKKKK, PamDhc-SKKKK, Pam-CSKKKK, Dhc-SKKKK 및 FSL-1로 구성된 군으로부터 선택되는 어느 하나 이상인, 백신 아쥬반트.
- 제1항에 있어서, 면역활성물질을 추가로 포함하는, 백신 아쥬반트.
- 제3항에 있어서, 상기 면역활성물질이 폴리(I:C), QS21, MPLA(Monophosphoryl Lipid A), CpG 및 플라겔린(Flagellin)으로 구성된 군으로부터 선택되는 어느 하나 이상인, 백신 아쥬반트.
- 제4항에 있어서, 상기 폴리(I:C)가 50 내지 5,000 bp의 길이인, 백신 아쥬반트.
- 제1항의 아쥬반트 및 항원을 포함하는 백신 조성물.
- 제6항에 있어서, 상기 항원이 병원체의 단백질, 재조합 단백질, 당단백질, 펩티드, 다당류, 지질다당류 또는 폴리뉴클레오티드인, 백신 조성물.
- 제6항에 있어서, 상기 항원이 세포 또는 바이러스로부터 유래된 것인, 백신 조성물.
- 제6항에 있어서, 상기 항원이 바리셀라-조스터 바이러스(Varicella-Zoster Virus)의 gE(glycoprotein E) 항원, 일본뇌염 바이러스의 gE(glycoprotein E) 항원 및 계절형 불활화 독감 바이러스(seasonal inactivated influenza virus) 항원으로 구성된 군으로부터 선택되는 어느 하나 이상인, 백신 조성물.
- 제6항에 있어서, 상기 백신이 세포성 면역반응을 유도하는, 백신 조성물.
- 제6항에 있어서, 상기 백신이 Th1 면역반응을 증진시키는, 백신 조성물.
- 제6항의 백신 조성물을 유효성분으로 포함하는 바이러스의 감염 예방 또는 치료제.
- 제6항의 백신 조성물을 유효성분으로 포함하는 암의 예방 또는 치료제.
- 제6항의 백신 조성물을 개체에 투여하는 단계를 포함하는 바이러스의 감염 예방 또는 치료 방법.
- 제6항의 백신 조성물을 개체에 투여하는 단계를 포함하는 암의 예방 또는 치료 방법.
- 바이러스의 감염 예방 또는 치료를 위한 약제의 제조에 사용하기 위한 제 6항의 백신 조성물의 용도.
- 암의 예방 또는 치료를 위한 약제의 제조에 사용하기 위한 제 6항의 백신 조성물의 용도.
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201880052947.3A CN110996999A (zh) | 2017-08-16 | 2018-08-10 | 包含插入有脂肽的脂质体作为有效成分的疫苗佐剂及其用途 |
US16/639,302 US11612650B2 (en) | 2017-08-16 | 2018-08-10 | Vaccine adjuvant comprising lipopeptide-inserted liposome as effective ingredient and use thereof |
JP2020531405A JP7080513B2 (ja) | 2017-08-16 | 2018-08-10 | 有効成分としてリポペプチド挿入リポソームを含むワクチンアジュバントおよびその使用 |
CA3072895A CA3072895C (en) | 2017-08-16 | 2018-08-10 | Vaccine adjuvant comprising lipopeptide-inserted liposome as effective ingredient and use thereof |
EP18846714.6A EP3669891A4 (en) | 2017-08-16 | 2018-08-10 | VACCINE ADJUVANS WITH LIPOPEPTIDE-INSERTED LIPOSOME AS THE ACTIVE SUBSTANCE AND USE OF IT |
AU2018317120A AU2018317120B2 (en) | 2017-08-16 | 2018-08-10 | Vaccine adjuvant comprising lipopeptide-inserted liposome as effective ingredient and use thereof |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2017-0103788 | 2017-08-16 | ||
KR20170103788 | 2017-08-16 | ||
KR10-2018-0005418 | 2018-01-16 | ||
KR1020180005418A KR102098097B1 (ko) | 2017-08-16 | 2018-01-16 | 리포펩티드가 삽입된 리포좀을 유효성분으로 포함하는 백신 아쥬반트 및 이의 용도 |
Publications (3)
Publication Number | Publication Date |
---|---|
WO2019035605A2 WO2019035605A2 (ko) | 2019-02-21 |
WO2019035605A3 WO2019035605A3 (ko) | 2019-04-25 |
WO2019035605A9 true WO2019035605A9 (ko) | 2019-06-06 |
Family
ID=65362200
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2018/009173 WO2019035605A2 (ko) | 2017-08-16 | 2018-08-10 | 리포펩티드가 삽입된 리포좀을 유효성분으로 포함하는 백신 아쥬반트 및 이의 용도 |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2019035605A2 (ko) |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE50309916D1 (de) * | 2002-04-04 | 2008-07-10 | Helmholtz Infektionsforschung | Verwendung eines lipopeptids oder lipoproteins als adjuvans bei therapeutischer oder prophylaktischer vakzinierung |
WO2012116225A2 (en) * | 2011-02-24 | 2012-08-30 | Oncothyreon Inc. | Muc1 based glycolipopeptide vaccine with adjuvant |
RU2580003C2 (ru) | 2011-02-24 | 2016-04-10 | Могам Байотекнолоджи Рисерч Инститьют | Новые штаммы вируса ветряной оспы и противовирусная вакцина против ветряной оспы и опоясывающего лишая, в которой применяются такие штаммы |
KR101501583B1 (ko) * | 2013-03-29 | 2015-03-12 | 주식회사 차백신연구소 | 리포펩티드 및 폴리(i:c)를 포함하는 아쥬반트 및 이를 이용한 개선된 제형의 백신 조성물 |
SG11201509357WA (en) * | 2013-05-14 | 2015-12-30 | Merck Patent Gmbh | Method of treating lung cancer by vaccination with muc-1 lipopeptide |
KR101723605B1 (ko) | 2014-10-21 | 2017-04-07 | 진원생명과학 주식회사 | 대상포진 예방 및 치료용 dna 백신 조성물 및 이를 이용한 vzv 항원에 대한 t세포 활성화 방법 |
-
2018
- 2018-08-10 WO PCT/KR2018/009173 patent/WO2019035605A2/ko unknown
Also Published As
Publication number | Publication date |
---|---|
WO2019035605A3 (ko) | 2019-04-25 |
WO2019035605A2 (ko) | 2019-02-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA3072895C (en) | Vaccine adjuvant comprising lipopeptide-inserted liposome as effective ingredient and use thereof | |
WO2019209079A1 (en) | Nucleic acid molecules inserted expression regulation sequences, expression vector comprising nucleic acid moleclues and pharmaceutical use thereof | |
WO2021172971A1 (ko) | 수두 대상포진 바이러스 융합 단백질 및 이를 포함하는 면역원성 조성물 | |
WO2018124615A1 (ko) | 대상포진 백신 조성물 | |
EP3440096A1 (en) | A peptide with ability to penetrate cell membrane | |
WO2018080253A1 (ko) | 면역반응 조절물질 및 양이온성 리포좀을 포함하는 면역증강용 조성물 및 이의 용도 | |
WO2020076079A2 (ko) | 락토바실러스 카제이 유래의 두 종류 프로모터를 이용한 두 가지 목적단백질의 동시 표면발현벡터 및 이를 이용한 단백질의 미생물표면 발현 방법 | |
WO2019203599A1 (ko) | 스트렙토코커스 뉴모니애 협막 다당류 및 그의 면역원성 접합체 | |
WO2019035605A9 (ko) | 리포펩티드가 삽입된 리포좀을 유효성분으로 포함하는 백신 아쥬반트 및 이의 용도 | |
WO2020005028A1 (ko) | 중증 열성 혈소판 감소 증후군(sfts) 바이러스 감염 질환 예방 또는 치료용 백신 조성물 | |
WO2022191377A1 (ko) | Sars-cov-2 예방 백신 조성물 | |
WO2020246750A2 (ko) | 안정화된 핵산 면역증강제를 함유하는 약학 조성물 | |
WO2019194393A1 (ko) | 페리틴 자가조립체에 항원 펩타이드 및 면역 증강제가 결합된 나노 입자 및 이의 용도 | |
WO2019066437A1 (ko) | 가용성 변형 호흡기 융합세포 바이러스 (rsv) f 단백질 항원 | |
WO2022191555A1 (ko) | Rna의 체내 전달용 조성물 및 이의 제조방법 | |
WO2022119380A1 (ko) | 신규한 ace2 변이체 및 그의 이용 | |
WO2022035246A1 (ko) | B형 간염 바이러스 유래 폴리펩티드를 포함하는 면역 어쥬번트 | |
WO2024053934A1 (ko) | 에멀전 제형의 면역증강제 조성물 및 이의 제조 방법 | |
WO2023075421A1 (ko) | 수지상 세포를 표적하는 신규한 펩타이드, 및 이를 포함하는 암 치료용 조성물 | |
AU2020299074B2 (en) | Novel ribonucleic acid and pharmaceutical composition based on the same | |
WO2024014943A1 (ko) | Sars-cov-2 백신 부스터 조성물 | |
WO2022250416A1 (ko) | 리포펩타이드와 폴리(i:c) 아쥬번트를 이용하는 면역항암치료제 조성물 | |
WO2022015124A1 (ko) | 중증급성호흡기증후군 코로나바이러스 2 감염 예방용 백신 조성물 | |
WO2023229446A1 (ko) | 그람 음성 박테리아 외막 유래 나노소포체의 제조 방법 및 이의 용도 | |
WO2021125891A1 (ko) | A형 간염 바이러스의 제조방법 및 상기의 방법에 따라 제조된 a형 간염 바이러스 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 18846714 Country of ref document: EP Kind code of ref document: A2 |
|
ENP | Entry into the national phase |
Ref document number: 3072895 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2020531405 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2018317120 Country of ref document: AU Date of ref document: 20180810 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2018846714 Country of ref document: EP Effective date: 20200316 |